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ABSTRACT 
Functional and Structural Studies of Influenza B Virus Hemagglutinin 
by 
Fengyun Ni 
Influenza A and B viruses are major causes of seasonal flu epidemics each 
year.  Hemagglutinin (HA) mediates the binding of virus to host cell and the fusion 
with host membrane.  The crystal of HA in complex with antibody that reveals the 
mechanism by which antibody recognizes HA may not diffract to high resolution, 
thereby preventing the accurate interpretation of the structural model. The 
application of normal mode refinement that aims for improving the structure 
quality at the low resolution is tested.  These studies provide some guidelines for 
future refinement of HA-antibody complex structures.  By comparing the residues 
constituting the base of the receptor binding site of influenza A and B virus HAs, it is 
found that they share some similarities, except for a Phe at position 95 of influenza 
B virus hemagglutinin (BHA) versus Tyr in of influenza A virus hemagglutinin (AHA).  
The recombinant protein BHA containing the F95Y mutation exhibits the increased 
receptor binding affinity and specificity.  However, recombinant viruses with the 
Phe95Tyr mutation show lower erythrocyte agglutination titer and decreased 
binding abilities with different cell lines.  The replication of the Phe95Tyr mutant 
virus in mice is also attenuated.  These data suggest that the increased receptor 
binding ability of HA alone is not advantageous to the pathogenesis of the viruses.  
 
 
 
The structure of BHA2 (a portion of BHA near the C-terminus) at the post-fusion 
state has been determined to 2.45 Å resolution.  This protein forms a hairpin-like 
conformation rich in -helices.  About 70 residues from the N-terminus is a three-
stranded coiled coil, and the remaining of the protein packs in anti-parallel against 
the groove formed by the central helices.  In the post-fusion state of BHA2, the helix 
converted from the B-loop in pre-fusion state contacts the C-terminal fragment of 
this protein with more hydrophobic interactions as compared to AHA2.  This 
structure illustrates the distinct stabilization strategy employed by BHA2 to form a 
post-fusion state that resembles that for AHA2.  These studies will further the 
understanding of BHA with respect to its role in receptor binding ability and fusion. 
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 1 
Chapter 1  
Introduction 
1.1.  Influenza virus 
Three genera of influenza viruses (A, B, and C) are members of 
Orthomyxoviridae family (1).  The viruses in the family of Orthomyxoviridae have a 
negative-sense, single-stranded, and segmented RNA genome (1).  Human Influenza 
A and B viruses can cause disease in people of any age, and they remain as a leading 
cause of mortality and morbidity worldwide.  Infections of Influenza C viruses cause 
a milder respiratory illness and are thought to be endemic (2).  Health organizations 
including the U.S. Food and Drug Administration (FDA), World Health Organization 
(WHO), the U.S. Centers for Disease Control and Prevention (CDC) and other 
institutions are devoted to the identification of the most common influenza viruses 
during the upcoming flu season.  The vaccine against those identified viruses are 
produced to protect people from potential infections of influenza viruses. 
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Influenza A, B, and C viruses evolved from a common ancestor, and it is 
proposed that influenza B viruses diverged from influenza C viruses about 8,000 
years ago; influenza A viruses diverged from influenza B viruses about 4,000 years 
ago; and the different subtypes of influenza A viruses diverged about 2,000 years 
ago based on the sequence comparison of hemagglutinin (3).  Evolutionary rates for 
influenza A viruses are much faster than influenza B and C viruses (4).  It is 
postulated that the transmission of influenza A viruses to human happened less than 
150 years ago, possibly from birds (5).  Influenza A viruses have a wide host range, 
including humans, avian species, and domestic animals (6); influenza B viruses only 
infect humans, seals, and ferrets (7–9); and influenza C viruses only infect humans, 
pigs and dogs (9).  Recent epidemic among New England harbor seals caused by a 
mutant avian H3N8 influenza A virus leads to concerns about transmission to 
human (10).  The evolution of influenza A viruses has not reached an adaptive 
equilibrium, whereas influenza B and C viruses with limited host range are 
considered to have achieved an evolutionary stasis in human (5). 
Despite the effort to develop vaccine against influenza virus, this virus is still 
able to elude host adaptive immunity by mutation of its genome, resulting in a new 
strain of influenza virus that cannot be recognized by the antibodies against the 
older strain of virus (11).  The mutations mostly happen on the surface proteins of 
influenza viruses, hemagglutinin and neuraminidase, because these two proteins are 
the main antigens recognized by the antibodies.  The continuous genetic change and 
antigenic change of influenza viruses is often referred as antigenic drift, and this 
process is common in both influenza A and B viruses (12, 13).  Another type of 
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change that only occurs in influenza A virus is called antigenic shift (14).  The 
antigenic shift is a more dramatic and abrupt change due to the recombination of 
viral genetic materials from more than one original strain that results in a new 
subtype of influenza virus with a new combination of hemagglutinin and 
neuraminidase proteins (15). 
Based on the antigenic properties of hemagglutinin (H) and neuraminidase 
(N) antigens, influenza A viruses are classified into different subtypes depending on 
the types of hemagglutinin and neuraminidase present on the virus surface (1, 4).  
There are 16 distinct subtypes of hemagglutinin and 9 subtypes of neuraminidase in 
wild waterfowl.  However, influenza B and C viruses do not have subtypes (4). 
The nomenclature of influenza viruses includes the type of virus (A, B or C), 
the host of origin (e.g., swine, chicken, etc., omitted if human.), the place of isolation 
(e.g., Texas, California, etc.), the strain number, the year of isolation and subtypes 
(only for influenza A viruses) (16).  For example, A/Victoria/361/2011 (H3N2), 
which is one of the vaccine viruses in 2012-2013 influenza season, stands for the 
361st strain of an H3N2 subtype influenza A virus isolated from a human in Victoria 
in 2011. 
1.2. Morphology and genome of influenza virus 
As an enveloped virus, influenza virus derives its lipid bilayer from the 
plasma membrane of the host cell (Figure 1.1, grey circle).  There are two 
glycoproteins on the surface of the virion, hemagglutinin (HA) and neuraminidase 
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(NA).  The envelope also harbors the ion channel protein M2.  A layer of the matrix 
protein 1 (M1) that forms an ordered structure lies adjacent to the lipid envelope.  
Each of the eight pieces of RNA segments is associated with the polymerase subunits 
(Polymerase Basic 1[PB1], Polymerase Basic 2 [PB2] and Polymerase Acid [PA]) and 
nucleoprotein (NP) oligomers in the form of ribonucleoprotein (RNP) that locates in 
the core of the virion (17).  Nonstructural protein (NS2) also exists in the viral 
particle (18).  Influenza viruses display multiple morphologies, including spherical 
viral particles with about 100 nm in diameter and elongated filamentous viral 
particles with about 100 nm in diameter and up to 20 m in length (19–21). 
Both influenza A and B viruses have eight RNA segments including PB2, PB1, 
PA, HA, NP, NA, M, and NS according to the segment sizes.  The genome of influenza 
A virus encodes 12 proteins in total, whereas the genome of influenza B virus 
encodes 11 proteins in total.  Near the 5’ end of the second RNA PB1 of influenza A 
virus, an alternative open reading frame gives rise to the 87-amino acid-long PB1-F2 
protein (22), which are not observed in influenza B virus.  The PB1 RNA also 
encodes the N-terminal truncated form of protein N40 (23).  The sixth RNA NA of 
influenza B virus also encodes the 100-amino acid-long NB protein (24), which does 
not exist in influenza A virus.  The seventh RNA M of influenza A virus not only 
encodes the M1 protein, but also results in a spliced mRNA encoding the M2 protein 
(1).  The corresponding RNA M of influenza B virus also encodes the M1 protein, but 
utilizes a distinct “stop-start” translation mechanism to translate the BM2 protein 
(25). 
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Figure 1.1 The generic structure of influenza virus.  The lipid bilayer envelope of 
influenza virus is shown in grey, the layer of the M1 protein that lies under the envelope is 
shown in black.  The protein components are shown in different shapes and colors as labelled in 
the figure.  The viral ribonucleoproteins are shown in eight segmented pieces with different 
lengths. 
1.3. The life cycle of influenza virus 
The sialic acids (SAs) on the cell surface are the common receptors for 
influenza A and B viruses, where surface protein HAs of influenza viruses interact 
with the receptors (Figure 1.2).  The terminal sialic acid is connected to the 
penultimate galactose (Gal) with either (2,3)- or (2,6)-linkage.  Human tracheal 
epithelial cells are reported to have mainly SA(2,6)Gal sugar moieties (26), while 
duck gut epithelium contains mainly SA(2,3) moieties (27).  The receptors with 
(2,6)-linked sialic acid are often called “human-like receptors”; similarly, the 
receptors with (2,3)-linked sialic acid are often called “avian-like receptors”.  The 
type of the receptors on the host cell surface determines the attachment efficiency 
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(leading to the infection) of influenza virus.  In a recent study on the adaptation of 
an reassortant avian H5N1/human H1N1 virus in ferret (28), it shows that the HA of 
avian H5N1 which only binds to SA(2,3)Gal shifts to bind SA(2,6)Gal after 
mutations of two key amino acids in HA, demonstrating the adaptive ability of 
influenza viruses to fit the receptor requirement on the host cells for a better 
attachment.  Indeed, the viral HA is usually known as a host-range determinant (29, 
30). 
Following the attachment, the influenza virus is internalized mainly by 
clathrin-mediated endocytosis (31).  Other internalization pathways include those 
through caveolae, through non-clathrin/ non-caveolae, and through 
macropinocytosis (32).  The low pH environment in the endosome triggers the 
conformational change of HA, and activates the fusion of endosomal and viral 
membranes, releasing the RNPs into the cytoplasm of host cell.  The M2 protein with 
ion channel activity allows the influx of protons into the virion, and the protons 
cause the dissociation of the RNPs from the other viral components, thus facilitating 
the uncoating of influenza virus (33).  The nuclear localization signals (NLSs) are 
found on all the proteins of the RNP complex (PB1, PB2, PA, and NP) to interact with 
the nuclear import machinery for the import of viral RNA into the nucleus (1). 
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Figure 1.2 Life cycle of the influenza virus.  The infection of the influenza virus begins 
with the attachment of virus particle to the recepotrs on the host cell surface.  The bound virus 
is internalized through endocytosis.  With the elevated pH in the endosome, the virus is fused 
with the endosomal membrane.  The fusion and the uncoating of the virus result in the release 
the viral genome into the cytoplasm.  The viral genome enters the nuclear through the nuclear 
import machinery.  The vRNA is replicated by the viral polymerase complex, and the viral mRNA 
is also synthesized for the expression of viral proteins.  The expressed viral polymerase and 
nucleoprotein associate with the vRNA to form new RNPs. The M1 and NS2 proteins bind with 
RNPs for their transportation.  The NS1 protein is the main effector to suppress host immune 
response.  The HA, NA, M2 proteins concentrate on the apical membrane for budding.  The NA 
protein cleaves the sialic acid to release the progeny virions. 
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After entering the nucleus, the negative-sense viral RNA (vRNA) serves as the 
template to make a full-length positive-sense copy of complementary RNA (cRNA) 
and in turn serves as a template to make more vRNA, where different subunits of 
viral polymerase complex are involved in these steps (34).  On the other hand, the 
vRNA is also transcribed into messenger RNA (mRNA) that is an incomplete 
products from vRNA template (34).  The viral polymerase complex snatches a 5’-cap 
from host pre-mRNA transcripts to be added at the 5’-end of viral mRNA, and this 
process is catalyzed by the cap-binding function of PB2 (35) and endonuclease 
activity of PA (36).  Thus, the cellular RNA polymerase II is utilized to initiate the 
synthesis of influenza virus mRNA. 
The viral gene expressions are temporally regulated (1).  At the early stages, 
the synthesis of NP and NS1 proteins is predominant possibly because of the 
particular roles of these proteins in the virus life cycle at the early stages (37).  The 
NP protein is required for the assembly of newly replicated vRNA into RNP (38) 
while the NS1 protein is the important virulence factor of influenza virus to inhibit 
the host innate and adaptive immunity (39).  The synthesis of HA, NA and M1 
proteins is delayed (37).  The HA and NA proteins are involved in the budding of 
progeny virions and the M1 protein together with NS2 dictates the nuclear export of 
RNP, and all these proteins are required at the later stages of virus life cycle (40). 
The HA, NA, and M2 proteins concentrate at the apical membrane of 
polarized cells through their apical sorting signals and their interactions with lipid 
raft (41).  The M1 protein serves as the recruiter to associate RNP with the 
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membrane at the budding site (42).  The accumulation of the M1 protein also 
initiates the outward curvature of the apical plasma membrane, leading to the 
budding process (41).  After the membrane fuses at the base of the bud, the 
enveloped virus still attaches to the host cell via the interaction of HA with the 
receptors on the cell surface.  The NA protein is required to cleave the sialic acids in 
order to release the viral particles, and it also promotes the spread of the viral 
particles to infect the surrounding cells (40). 
HA is a type I integral membrane protein (Figure 1.3), it is expressed as a 
precursor, called HA0.  HA0 has a signal peptide at its N-terminus that directing its 
transportation to the cell surface.  HA0 can be cleaved to HA1 and HA2.  HA2 has a 
fusion peptide at it N-terminus.  The transmembrane domain is located at the C-
terminus of HA2.  
 
Figure 1.3 Linear sequence structure of hemagglutinin 
HA mediates two important steps in the life cycle of influenza virus, binding 
and fusion; and it is also considered as one of the determinants for host switching 
(29, 30).  The studies on HA include the structural basis, the receptor binding 
specificity, the fusion ability, its interaction with antibodies, and the role in virus 
pathogenesis; all investigations are aimed to establish a more effective method to 
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fight against this lingering health threaten.  As an effort to contribute more 
understandings on the influenza virus, influenza B virus HA (BHA) is chosen to 
deeply study its structure and function. 
1.4. The anisotropic B-factor refinement 
Structural characterization of the proteins of influenza virus provide the 
basic information for rational design of the anti-virus drugs and vaccines (43).  
Especially, the structure of HA in complex with antibody illustrates the interaction 
pattern utilized by antibody to recognize the HA antigen.  By searching the protein 
data bank, it is found that many HA-antibody complex structures were determined 
at resolution below 3 Å (44–47).  The low-resolution feature of these structures 
might prevent the accurate elucidation of the interactions in the model.  As an 
attempt to improve the structure quality, the application of normal mode 
refinement (48) for the structures determined at the low resolution is tested. 
For structural refinement in X-ray crystallography, temperature B-factors are 
used to take into account structural deviations from average positions of atoms.  
Conventionally, the atomic positional deviation is modeled as a spherical Gaussian, 
and a single scalar constant, the isotropic B-factor, is used to model the temperature 
factor for each atom independently.  However, the large number of independent 
thermal parameters in the isotropic B-factor model, generally equal to the number 
of non-hydrogen atoms, imposes a severe burden for lower-resolution refinement 
due to low data-to-parameter ratio (risk of over-fitting).  Moreover, the 
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independence among atomic thermal factors across proteins, in many cases, results 
in poor interpretation of collectiveness of molecular motions.  This problem is a 
particularly severe for large and flexible complex structures where functions often 
involves long-range collective deformations.  Finally, many large complexes contain 
highly flexible structural components that undergo orientation-specific (anisotropic) 
deformations.   Ideally, anisotropic B-factors should be used for a more accurate 
description of those deformations.  However, very frequently, the highly flexible 
components in large complexes compromise the resolution of diffraction, making 
impossible a full-scale anisotropic refinement that requires three positional and six 
thermal parameters for each atom for many such systems. 
1.4.1. Normal mode refinement 
Normal mode refinement (NMRef) provides a method to overcome the issues 
discussed above, because this approach can describe the collective motion with a 
small set of low-frequency modes.  The idea of applying NMRef to X-ray 
crystallography was first proposed about 20 years ago, but successfully application 
to data with only moderate diffraction resolution data was achieved only recently, 
and was based on a new elastic network model for C-coarse-grained normal mode 
calculation to avoid the so-called “tip effect” (49). 
In the new elastic network model, an extra term (Equation 1.1) was added to 
the conventional potential function with its minimum unchanged, while imposing a 
scaling factor on those flexible degrees of freedom.  In this way, the new method 
could retain the advantage of conventional elastic normal mode analysis (eNMA) 
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that no initial energy minimization is needed; and meanwhile, this method 
suppressed the tip effect by attributing a large force constant to the flexible region. 
 
 
Equation 1.1 Potential function for the new elastic network model 
There are two important parameters to implement the new potential 
function as shown in formula 1.1.  One is the cutoff distance (rc) in the Heaviside 
step function hij, specifying the effective scope in which the coarse-grained points 
would be included in the calculation.  The other one is scaling factor () in the extra 
term, representing the amount of stiffness that would be introduced to the angular 
terms.   These two parameters could be adjusted to obtain more physically 
meaningful normal modes. 
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With normal modes in hand, the Debye-Waller factor could be expressed in 
Equation 1.2 
 
Equation 1.2 Debye-Waller factor 
Here, Ej is a 3×M eigenvector matrix for atom j with each column vector 
representing one normal mode, where M is the number of low-frequency modes.  
The variances of mm = <mm> represent the contributions from the effective 
normal modes, while the co-variances of mn = <mn> represent the contributions 
from the mode-mode coupling, causing the orthogonal rotation of the normal mode 
eigenvectors.  To assure the positive semi-definiteness of matrix , it is expressed in 
terms of a lower triangular matrix as =T [2-9].  In the refinement, the elements 
of matrix  are treated as independent parameters for the minimization of the 
crystallographic residual. If there are M low-frequency modes used in the 
refinement, the number of the parameters accounting for the internal motion by 
normal mode is M(M+1)/2, which would be much smaller than that used for 
conventional isotropic B-factor refinement (50). 
1.4.2. Translation, libration and screw-rotation (TLS) refinement 
Whereas normal modes could describe the internal motion of the 
macromolecule in its biological aspects, TLS represents the external motion of the 
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pseudo-rigid bodies within the crystal (51).  The bodies could be the whole molecule, 
functional domains, or secondary elements.  The movement of a rigid body is 
described as the combination of a rotation about an axis passing through the origin 
and a translation of the origin (52). 
The displacement of an atom in a rigid body can be expressed by a set of 20 
parameters, constituting three 3×3 tensors: symmetrical tensors T and L describing 
the translational and rotational components of the rigid-body displacement and 
generally non-symmetric tensor S describing the correlation between translational 
and rotational displacements (53, 54).  The number of the total parameters used in 
the refinement depends on how many rigid bodies are defined in the asymmetric 
unit. 
Despite its widely observed success, TLS refinement has certain limitations, 
most of which are related to its rigid-body assumption.  For example, the motions 
between rigid-bodies are not interdependent, thus making the TLS model less 
collective for large-conformational deformations.  Another issue of TLS is that the 
grouping scheme in multi-group refinement can be tricky.  The best systematic way 
of grouping is derived from the distribution of converged isotropic B-factors.  Such a 
feature raises the issue of reliability, or even the possibility, of successful grouping 
in cases where the isotropic B-factors are poorly, or not at all, converged  a case 
often seen in structural refinement at moderate resolutions. 
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1.4.3. Selection of the structures  
A set of systems determined at the low resolution are tested to demonstrate 
when and how NMRef is employed to improve structural refinement in X-ray 
crystallography.  In the eight studied structures, five of them are complex structures, 
while the other three are determined at 3.5 A to 3.9 Å. 
The first system is the structure of the voltage-dependent potassium channel 
(KvAP) in complex with monoclonal Fv fragment at 3.9 Å (PDB accession code: 2A0L) 
(55).  The voltage-dependent potassium channel forms the potassium selective 
pores across the membrane to allow the flow of potassium in responsible to the 
membrane potential, and the monoclonal Fv fragment was included to improve the 
crystal resolution (55). 
The second one is the structure of the CorA magnesium transporter at 3.9 Å 
(PDB accession code: 2BBJ) , which is responsible for the uptake of magnesium in 
prokaryotes (56). Several principles of transportation of magnesium through the 
CorA magnesium transporter were proposed based on the structure analysis (56). 
The third one is the complex structure of yeast Sec13/31 at 3.3 Å (PDB 
accession code: 2PM9), which is one of the assembly units of COPII coat (57).  By 
fitting this crystal structure into an electron microscopy density map of COPII cage, 
a molecular model of the COPII cage was constructed (57). 
The fourth one is the structure of HIV-1 reverse transcriptase (RT) in 
complex with Janssen-R185545 (an anti-AIDS drug candidate) at 3.0 Å (PDB 
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accession code: 1SUQ), that reveals the conformation of drug that adopted to fit into 
the hydrophobic binding pocket on HIV-1 RT (58). 
The fifth one is the structure of an open state of the mechanosensitive 
channel (MscS) at 3.45 Å (PDB accession: 2VV5), that shows a pore with 13 Å in 
diameter (59).  The mechanism that underlies the gating of the MscS was suggested 
based the structure (59). 
The sixth one is the structure of 1998 human influenza virus neuraminidase 
in complex with its antibody at 3.0 Å (PDB accession: 2AEQ) (60).  The structure 
illustrates a novel interaction pattern as compared to other NA-antibody structures, 
and it supports the concept that antibody selection of NA escaping variants is 
important for the antigenic drift in human H3N2 influenza viruses (60). 
The seventh one is the structure of chicken embryo lethal orphan (CELO) 
adenovirus major coat protein hexon at 3.9 Å ( PDB accession code: 2INY) (61).  A 
remarkable channel with 100 Å in diameter that runs through the entire hexon 
crystal reveals its potential application as nano-material (61). 
The last system is the complex structure of Deinococcus radiodurans RecR 
and RecO (drRecOR) at 3.8 Å (PDB accession code: 2V1C) (62).  The complex shows 
a RecR:RecO molecular ratio of 2:1, in consistence with the previous biochemical 
studies (62).  The structural analysis together with the mutagenesis studies 
indicates a mechanism that underlies the recognition of stalled DNA replication 
forks by drRecOR (62). 
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All these systems are featured as low data-to-parameter ratio, un-converged 
B-factor profile, which are possible to happen to the crystal structures of HA-
antibody complex.  The studies on these systems with normal mode refinement 
should provide some useful guidelines for the further refinement of HA-antibody 
structures. 
1.5. Receptor binding ability of BHA 
The ability of influenza A virus to efficiently infect human population is 
correlated with the high affinity of HA to (2,6)-linked cell-surface sialic acid 
receptors with a characteristic umbrella-like structural topology (63, 64).  The 
receptors bind to a shallow receptor-binding site (RBS) in the globular domain of 
HA formed by three key residues that are absolutely conserved among all known 
influenza A virus HA (AHA) glycoproteins, Tyr98, Trp153, and His183 (Figure 1.4) 
(H3 AHA numbering) (65). 
Different from influenza A virus, influenza B virus does not have subtypes.  
Instead, currently circulating influenza B viruses belong to either Yamagata lineage 
or Victoria lineage that diverged from each other in the early 1970s (66, 67).  Most 
strikingly, as mentioned above, influenza B virus has a very limited host range, 
circulating almost exclusively among humans (9).  In measuring the binding affinity 
of influenza B virus to receptor analogs in vitro, it was found that influenza B viruses 
overall have lower binding affinities as compared to those of influenza A virus (68). 
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Our group has determined the crystal structures of influenza B virus HA 
(BHA) in various states (69, 70).  The overall structure of BHA is similar with that of 
AHA (69).  Comparison of the structures of influenza AHA and BHA glycoproteins 
revealed a critical difference in the receptor binding sites: Tyr98 in AHA versus 
Phe95 in BHA (based on the numbering of influenza B/Hong Kong/8/73 HA) (69, 
70).  The hydroxyl group of Tyr98 in AHA contributes two hydrogen bonds to the 
bound Sia-1 moiety, which are lost in BHA when Phe95 is present instead (Figure 
1.4B) (70).  It is hypothesized that the loss of the hydroxyl group at Phe95 in BHA 
might contribute to the low binding affinity of influenza B virus (71). 
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Figure 1.4 Comparison of the receptor-binding sites of influenza A and B virus 
HA.  Shown are (A) influenza A/Hong Kong/68 H3 HA (PDB accession code: 1HGE);  (B) 
influenza B/Hong Kong/8/73 HA (PDB accession code: 2RFU);  (C) influenza B/Hong 
Kong/8/73 HA with the mutation Phe95Tyr modeled in silico. 
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In order to test this hypothesis, the Phe95Tyr mutation was generated by 
using site-directed mutagenesis.  Although naturally occurring influenza B viruses 
generally have asparagine (Asn) and serine (Ser) at HA1 194 and 196 respectively, 
creating a glycosylation site at Asn194, this site was frequently abolished in egg-
adapted variants (72–78) and sporadic field isolates (79, 80), as a result of 
mutations at HA1 194 or 196 or both.  Thus, the mutation Phe95Tyr was 
constructed on BHA with (wild type) or without (Asn194Asp) a glycosylation site 
at HA1 194.  Recombinant BHA proteins are used to demonstrate the critical roles of 
Phe95 in determining the binding affinity for a variety of sialic acid receptors and 
cultured cells.  Recombinant viruses are also generated by reverse genetics to 
characterize the role of Phe95 in receptor binding ability at virus level. 
1.6. Membrane fusion induced by HA 
Membrane fusion that results in the mixing of enveloped genomic materials 
with the contents of the host cell is an important step in viral life cycle (81).  Viruses 
utilize their surface proteins, usually called fusion proteins, to overcome the energy 
barrier required to merge the viral and host membranes (82).  Though the 
sequences and structures of fusion proteins from different families of viruses are 
extremely diversified, recent studies suggest a common mechanism by which fusion 
proteins proceed from initial pre-fusion states, through a six-helix bundle 
intermediate state, to the final trimeric hairpin structure.  The conformational 
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changes of fusion proteins can be triggered by either low pH, receptor binding or 
other novel factors (81, 83, 84). 
Among the many characterized fusion proteins, hemagglutinin of influenza A 
virus (AHA) serves as a paradigm to study the protein-mediated membrane fusion 
(Figure 1.5) (85).  The crystal structures for fusion-incompetent, pre-fusion and 
post-fusion states of AHA are well established by several groundbreaking papers (65, 
86–88).  The structure of the precursor of AHA (AHA0) shows that the C-terminus of 
HA1 and N-terminus of HA2 form a surface loop that is susceptible for cleavage by 
trypsin-like enzymes (Figure 1.5A), and HA1 acts like a clamp sitting atop the stem 
region formed by HA2 (86).  Cleavage of HA0 results in HA1 and HA2, which are 
linked together by one disulfide bond (Figure 1.5B).  The fusion peptide at the N-
terminus of HA2 inserts into a hydrophobic cavity near the bottom of the stalk (65). 
When pH decreases, HA1 dissociates from HA2 due to the protonation of 
multiple ionizable residues locating at the interface between HA1 and HA2 (Figure 
1.5C).  The loop-to-helix transition of the B-loop of HA2 in its pre-fusion state 
elongates the coiled-coil structure in the pre-fusion state, by the newly formed 
coiled-coil from helix B and helix A.  The elongated coiled-coil projects the fusion 
peptide into the target membrane (Figure 1.5D).  The loop-to-helix transition of the 
B-loop is central to the so-called “spring-loaded mechanism” that reflect the large 
free energies released from this transition and are utilized to overcome the energy 
barrier of membrane fusion (89–91). 
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A small part of helix C rearranges (Figure 1.5E) so that the hydrophobic 
interactions in this region are altered  (87, 88).  The rearrangement results in the 
formation of a six-helix bundle(Figure 1.5F), as accompanied by the curvature of 
both viral and host membranes.  The complete formation of the six-helix bundle is 
important for the fusion intermediate hemi-fusion, where only the inner lipid 
leaflets merge while the outer lipid leaflets remain intact (Figure 1.5G).  The HA2 
protein continues to collapse due to the interactions between the C-terminal 
segment and the groove formed by the central helices, until the fusion peptide and 
the transmembrane domain of HA are in close proximity (Figure 1.5H).  Multiple 
HA2 around the fusion site work together to open and enlarge the fusion pore, 
resulting in the mixture of viral and cell contents. 
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Figure 1.5 Model for the fusion process induced by HA. 
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Influenza B virus may cause other severe diseases, including myositis and 
leukopenia in children and is responsible for seasonal influenza epidemics every 2-4 
years (92–95).  As mentioned above, the structure of BHA in its pre-fusion state has 
only been determined recently and has provided much information on its 
antigenetic sites and receptor binding specificities (69, 70).  Hemagglutinin of 
influenza B virus (BHA) shares only 28% protein sequence identities with AHA (96).  
The mechanism underlying the fusion process induced by BHA is largely unknown 
without structural information of BHA at post-fusion state. 
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Chapter 2 
Methods and Materials 
2.1. Anisotropic B-factor refinement 
2.1.1. Normal mode refinement 
In order to eliminate the differences in R-factors from different refinement 
programs, the original model was first used as input to REFMAC5 (97) to update the 
R-factors, which were used in future comparison with normal-mode-refined 
structures.  In the normal-mode-based refinement, optimal values for cutoff 
distance and stiffness were empirically determined for each individual system, as 
judged by the lowest Rcryst- and Rfree-values in subsequent normal-mode refinement.  
A different number of normal modes (M), corresponding to a range of different 
refinement parameters (equals to M(M+1)/2 + 27), were used in normal-mode 
refinement to generate anisotropic B-factors.  The anisotropic B-factors then 
replaced the isotropic B-factors in the original model, which was then subject to 
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REFMAC5 (97) refinement with very tight geometric restraints for positional 
refinement.  The Rcryst- and Rfree-factors were monitored throughout, following the 
Equation 2.1: 
 
Equation 2.1 R-factor 
where the same set of free reflections used in the original structure 
determination was saved for calculation of the Rfree-factor. 
To compare with the isotropic B-factor profiles in the original model, the 
anisotropic B-factor profile of the normal-mode model was converted to isotropic 
ones by averaging the diagonal terms of anisotropic displacement parameters for 
each atom. 
2.1.2. TLS refinement on NMRef structures 
The normal-mode refined structure was submitted to the TLS Motion 
Determination (TLSMD) web server (51).  Models with different partition of each 
peptide chain would be generated. Each model was described by a tlsin file 
containing the parameters fitted for each TLS group and a xyzin file containing the 
atomic coordinates from the input model with modified Biso values.  These two files 
were used in REFMAC5 (97) to carry out five cycles of TLS-parameter refinement 

R 
Fobs(h)  Fcal(h)
h

Fobs(h)
h

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followed by five cycles of restrained positional refinement.  The TLS-parameter 
refinement and positional refinement were repeated until a lowest Rfree-value was 
achieved. 
2.2.  Functional study of Phe95Tyr mutation of BHA 
2.2.1.  Cells 
BHK21 (Baby hamster kidney cell), Vero (African green monkey kidney cell), 
293T (Human kidney cell), CV-1 (Green monkey kidney cell) and A549(Human lung 
cell) cells were maintained in DMEM (Dulbecco's Modified Eagle Medium) with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin in a CO2 incubator.  MDCK 
cells were maintained in EMEM (Eagle's Minimal Essential Medium) with 10% FBS 
and 1% penicillin-streptomycin. 
2.2.2.  Cloning, expression and purification of BHA and its mutants 
The cDNA encoding HA of influenza B/YM/73 (BHA) virus (a kind gift from 
Dr. Peter Palese) was cloned to pRB21 plasmid (a kind gift from Dr. Bernard Moss) 
to allow the expression in vaccinia systems (98).  Site-directed mutagenesis was 
used to introduce the Phe95Tyr, Asn194Asp and Phe95Tyr/Asn194Asp 
mutations into BHA (Agilent Technologies).  All the mutant constructs were fully 
sequenced.  The recombinant vaccinia viruses were generated by infecting CV-1 
cells with wild type virus vRB12 and then transfected with pRB21 vector containing 
BHA or its mutants (98).  All the constructs were expressed as the unprocessed HA0 
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containing a C-terminal trimerizing sequence from the bacteriophage T4 fibritin 
(foldon) to facilitate the trimerization and expression of HA in the absence of the 
transmembrane region (99) and contained a His-tag at the extreme C-terminus.  The 
CV-1 cells were maintained in DMEM medium supplemented with 10% fetal bovine 
serum (FBS).  For a typical preparation, 400 mL confluent CV-1 monolayer cells 
were infected by recombinant vaccinia viruses at a multiplicity of infection (MOI) of 
1.  After three days, the supernatant was collected and dialyzed against buffer of 20 
mM Tris-HCl (pH 7.2), 50 mM NaCl.  The soluble BHA was recovered from the 
supernatant by HisPur Cobalt Resin (Thermo Fisher Scientific Inc.)  The beads 
bound with BHA were treated with neuraminidase (Sigma) to prevent sialic acid-
mediated aggregation.  The BHA was eluted with 500 mM imidazole and was 
exchanged to buffer of 20 mM Tris-HCl (pH 7.2), 50 mM NaCl by three cycles of 
concentration and dilution with a 30 kD-cutoff centrifugal filter unit (Amicon), then 
subjected to anion-exchange (mono-Q 4.6/100 PE, GE Healthcare) and gel-filtration 
chromatography (Superdex 200 10/300 GL, GE Healthcare). The peak 
corresponding to the BHA-trimer was collected and concentrated.  Protein 
concentration was quantified by Bradford protein assay (100). 
2.2.3.  Dose-dependent glycan assay 
To characterize the receptor binding properties of BHA and its mutants, 
biotinylated (2, 3)-glycan, 3’SLN-LN-LN, and (2, 6)-glycan, 6’SLN-LN, from the 
Consortium of Functional Glycomics (www.functionalglycomics.org) were used in 
the dose-dependent glycan assay (64, 101).  LN represents lactosamine (Gal1-
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4GlcNAc), 3’SLN and 6’SLN represent Neu5Ac2-3 and Neu5Ac2-6 linked to LN, 
respectively.  The different glycans were first diluted to 2.4 M and loaded on to the 
streptavidin-coated high binding capacity 384-well plates (Pierce), followed by 
incubation at 4 degree overnight.  Excessive glycans were removed by washing with 
PBS three times.  The pre-complex of BHA, mouse anti-His antibody (0.2 mg/mL, 
Sigma) and anti-mouse-IgG antibody (2 mg/mL, Sigma) was prepared in a molar 
ratio of 4:2:1.  The mixture was incubated on ice for 20 minutes, and the pre-
complex was diluted to the expected concentration with 1% BSA in PBS.  Each 
glycan-coated well was then loaded with 50 L of the pre-complex of BHA and 
incubated at room temperature for 2 hours followed by wash with 0.05% Tween-20 
in PBS to remove any unbound pre-complex.  The Amplex Red Peroxidase Assay kit 
(Invitrogen) was used to measure the binding signal based on the HRP activity.  
Negative controls, where no pre-complexes were loaded in those wells, were 
included for each glycan, and the assays were performed in triplicate.  To quantify 
the binding affinity, the assays were performed at low BHA concentration range 
(0.05 to 1.0 g/mL) for 3’SLN-LN and 6’SLN-LN.  A linearized Hill equation was used 
to represent the binding of the pre-complex of BHA to the coated glycan (with the 
data from 0.05 to 1.0 g/mL) (64, 102). 
2.2.4.  Glycan microarray analysis 
The binding profile of purified influenza B virus hemagglutinin and its 
mutants to different glycans was determined by the Consortium of Functional 
Glycomics (www.functionalglycomics.org) using version 4.1 glycan array, which 
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contains 465 glycan structures in replicates of six.  The BHA proteins were first 
incubated with anti-penta His antibody (Qiagen) and Alexa488-labeled anti-mouse 
IgG (Invitrogen) on ice for 30 minutes.  The final concentration of BHA proteins used 
in the assay was 200 g/ml.  The protein mixture was then applied to a fresh 
hydrated glycan array under a cover slip.  The fluorescence signals were recorded.  
This assay is carried out by the Consortium of Functional Glycomics 
(www.functionalglycomics.org).  For those glycans with strong signals indicating 
good binding, the relative fluorescence  unit (RFU) value are about 10,000 to  50,000.  
To make the data clear, an arbitrary value of 5000 RFU is set to be the cutoff for all 
protein samples.  If the glycan shows signal below 5000 RFU, it is regarded as a 
weak or un-recognized glycan.  The glycans that did not show signals above 5000 
RFU for any of BHA or its mutants are not considered.  Most of those un-shown 
glycans are without sialic acids. 
2.2.5.  Red blood cell binding assay 
Thirty microliter Ni-NTA resin (Thermo Fisher Scientific Inc.) was loaded 
with 2.5 g BHA and incubated at room temperature for 2 hours.  The beads were 
centrifuged, and the unbound BHA in supernatant was removed.  The beads were 
then blocked with 3% BSA in PBS for 30 minutes.  The supernatant was removed 
after spinning down the beads, and the beads were washed with PBS extensively.  
The red blood cells (RBCs) were washed with Alsever’s solution until the 
supernatant is clear.  The RBCs were stored as 50% in Alsever’s solution after the 
final wash.  The RBCs were then added to the BHA-coated beads to a final 
31 
 
 
concentration of 0.5% and incubated at room temperature for 30 minutes.  Finally, 
the beads were washed gently with PBS for appropriate imaging under microscope. 
2.2.6.  Influenza A virus infection inhibition assay in MDCK cells 
For this assay, the BHA eluted from the Cobalt Resin was used. The purity of 
BHA was about 85% to 90% as determined by SDS-PAGE.  MDCK cells were seeded 
at appropriate concentration in a 96-well plate for 24 hours to achieve 100% 
confluency  for performing the assays .  The cell monolayer was washed with 
Dulbecco's phosphate-buffered saline (DPBS)  twice and complete Dulbecco's 
modified eagle medium (DMEM) (0.2% BSA, 25 mM HEPES in DMEM) once.  The 
expected amount of BHA was loaded into different wells and complete DMEM was 
added to make all the wells contain same volume.  After the plate was incubated at 
room temperature for 1 hour, 5 HAU (Hemagglutination units) per 50 l 1% human 
RBC of influenza A/Brisbane virus and TPCK-trypsin (final concentration was 2 
g/ml, Worthington) were added to wells, and the plate was incubated at 37 degree 
for 1 hour (5% CO2).  The supernatant was removed, and the wells were washed 
twice with complete DMEM.  Finally, each well was loaded with 100 l influenza 
virus growth medium (complete DMEM with 2 g/ml TPCK-trypsin).  After 24 hours 
of incubation, the supernatant was centrifuged (300 g, 15 minute) to pellet the 
cellular debris and used for the standard hemagglutination assay with 1% human 
RBC.  All assays were performed in triplicate. 
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2.2.7.  Cell-based enzyme-linked immunosorbent assay (ELISA) assay 
In order to quantitatively detect the binding of receptors on the cell surface 
to BHA, cell-based ELISA assay was carried out with three cell lines including MDCK, 
BHK21 and Vero in 96-well plates.  For this assay, the BHA eluted from the Cobalt 
resin was used. The confluent cell monolayer in white 96-well plate (FALCON) was 
first washed with DPBS and different amount of BHA (0.1, 0.2, 0.5, 1, 2, 5, 10, 15, 20, 
30 g/100l) diluted with 1% BSA in DPBS was added to different wells.  Complete 
DMEM was then added to take all wells to the same volume of solution.  The plate 
was incubated at room temperature for 1 hour.  The supernatant was removed and 
each well was washed with DPBS for three times followed by addition of 100 l 3.7% 
formaldehyde diluted in DPBS for 10 minutes.  The fixative was removed, and wells 
were washed with PBST (0.1% Triton X-100 in PBS [Phosphate buffered saline]) for 
three times.  The wells were then blocked with 10% FBS for 1 hour at room 
temperature followed by incubation with primary antibody (mouse anti-His 
antibody, Sigma, 1:4000 dilution with 1% BSA in PBST) for 1 hour at room 
temperature.  The wells were then washed three times with PBST.  As a final step, 
secondary antibody (HRP-conjugated anti-mouse-IgG, Sigma, dilution 1:40000) was 
added to the wells for 1 hour at room temperature.  After washing with PBST and 
PBS, signal from each well was measured with ECL reagent (Amersham).  All assays 
were performed in triplicate. 
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2.2.8.  Reverse genetics and virus stock preparation 
The plasmids for reverse genetics of influenza B/Lee/40 virus were generous 
gifts from Dr. Kawaoka (Department of Pathobiological Sciences, University of 
Wisconsin-Madison).  The protocol to generate recombinant influenza viruses was 
generally according to a previous report (103).  The mutations Phe95Tyr, 
Asn194Asp and Phe95Tyr/Asn194Asp were introduced to BHA by site 
mutation.  Co-cultures of 293T and MDCK in DMEM with 10% FBS were plated one 
day before.  Two microliter TransIT-LT1 (Panvera, Madison, WI) was used per one 
micro-gram plasmid.  The preparation of DNA-lipid complex was according to the 
manufacturer’s instructions.  The DNA-lipid mixture was added into the 293T-MDCK 
co-culture, and the plate was incubated at 33 degree.  After 16 hours, the medium 
was removed, and the cell monolayer was washed twice with OMEM.  Fresh OMEM 
with 1 g/ml trypsin was added, and the plate was further incubated for 48 hours.  
For virus with Phe95Tyr mutation in HA, 1 g/ml neuraminidase (Sigma) was 
added to compensate for the increased binding ability of this variant.  The 
supernatant was harvested and was then propagated on MDCK cells.  The 
supernatant containing viruses was then plaque-purified and was propagated twice 
in MDCK cells.  MDCK monolayer in T-75 flask after overnight incubation was 
washed with plain EMEM for three times, followed by infection of 1 ml virus at room 
temperature with occasionally gentle rocking.  After 1 hour, the inoculum was 
removed and 30 ml EMEM with 1 g/ml TPCK-trypsin was added.  The cells were 
incubated at 33 degree for 3 days until at least 70% cells shown cytopathic effect 
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(CPE).  The supernatant was harvested, and clarified at 2600 g for 5 min, and 
layered over a 25% sucrose cushion in NTE buffer (100 mM NaCl, 1 mM EDTA, 10 
mM Tris-HCl, pH 7.4).  The virus was concentrated by ultracentrifugation at 30,000 
rpm for 3 hours at 4 degree.  The virus pellet was re-suspended in NTE buffer, 
aliquoted, and stored at -80 degree.  The purified viruses were thawed before using, 
and the titer was determined with standard techniques. 
2.2.9.  Sequencing of virus stock 
The virus stock was sequenced to confirm the desired mutation in HA gene.  
QIAamp viral RNA kit was used to extract the virus RNA.  The HA gene was amplified 
with designed primers by QIAGEN Onestep RT-PCR kit.  The sequenced region 
included nucleotides from about 150 to 1600.  The viruses with Phe95Tyr, 
Asn194Asp and Phe95Tyr/Asn194Asp in HA gene have correct sequences.  
For the wild type virus, which was expected to have an Asn at site 194, it had the 
correct sequence after one passage in MDCK cells.  But the glycosylation site at HA1 
194~196 was quickly lost after the second passage in MDCK cells (Asn194 was 
mutated to Asp194 or Ser194 in five and one, out of six sequenced viruses, 
respectively).  Because Asn194 was not stable in MDCK cells, only viruses have 
Asn194Asp or Phe95Tyr/Asn194Asp in HA were used in the following 
studies. 
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2.2.10.  Replication of recombinant viruses in MDCK and mice 
For replication of recombinant viruses in MDCK, the cell monolayer was 
infected with viruses at MOI of 0.1.  The supernatant was harvested after 48 hours 
infection.  For the replication in mice, mice were administered virus intranasally at 
104 PFU, and lungs were harvested after 3 days of infection (This experiment was 
performed by Dr. Lin Liu at Dr. Innocent Nnadi Mbawuike’s lab, Department: 
Molecular Virology & Microbiology, Baylor College of Medicine).  The titers are 
determined by plaque assay in MDCK.  For plaque assay with 
Phe95Tyr/Asn194Asp virus, the plaque forms rod-like shape.  To get circle-
shape plaques, 1 g/ml neuraminidase (Sigma) was added. 
2.2.11.  Binding assay of recombinant viruses 
The binding of fluorescently labeled viruses to different cell lines was 
according to methods as reported (104).  First, virus (50 l) was incubated with 
Alexa 488 (25 g, Invitrogen) in the presence of 0.1 M NaHCO3 (pH 9.0) for 1 hour at 
37 degree.  Second, the excessive Alexa 488 was removed from the labeled virus by 
dialysis against PBS with 1 mM EDTA overnight at 4 degree.  Slide-A-Lyzer MINI 
Dialysis Devices (7K MWCO, Thermo Scientific) was used for the dialysis.  The 
labeled viruses were then used for the binding experiments on the next day.  Third, 
confluent BHK21, Vero, A549 and MDCK cells prepared in 96-well plate one day 
before were chilled at 4 degree for 1 hour.  The cell monolayer was overlaid with 
labeled viruses at a multiplicity of infection of 3 for 1 hour at 4 degree, washed with 
PBS for three times, and read by FLUOstar Omega (BMG LABTECH) using 
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excitation/emission at 485 nm/528 nm.  The binding assays were performed in 
triplicate.  The substrate MUNANA (2’-(4-methylumbelliferyl)--D-N-
acetylneuraminic acid) was used to assay for viral NA activity at 4 degree. 
2.3. Structure determination of BHA2 at the post-fusion state 
The protein HA2 of B/HK/73 with His-tag at its N-terminus was expressed in 
E. coli and successfully produced high quality diffraction data in our lab.  BHA2 was 
concentrated to 10 mg/ml, crystals were grown in a 290 K incubation room by 
hanging drop using a 1:1 ratio of protein solution to reservoir solution of 0.1 M 
ammonium citrate, 13.5% PEG3350 (pH 7.0).  The diffraction data were collected 
with LS-CAT beamlines at the Advanced Photon Source at the U.S. Department of 
Energy's Argonne National Laboratory (Chicago, IL).  The diffraction images were 
indexed and integrated by HKL2000 (105) or Mosflm (106, 107), followed by scaling 
using SCALA executed in the CCP4 suite (108).  The intensities were then truncated 
to structure factor amplitude by TRUNCATE in CCP4 (108).  Five percent of unique 
reflections were randomly chosen as test set for calculating the Free R value. 
The long helix of AHA2 (PDB accession code: 1QU1) including residues 37 to 105 
was pruned to C atoms by CHAINSAW in the CCP4 suite (108) and served as the 
search model for molecular replacement.  One copy of the model was found by 
AutoMR module implemented in Phenix (109).  The resulting -weighted 2FOFC 
map showed the densities for the other part of protein.  The residues were built into 
the density by Coot (110)or O (111).  The model was refined by Refmac5 (97)or 
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Refine module in Phenix.  The Figures for structural snapshots were generated by 
Pymol (112). 
 
 38 
Chapter 3 
Results 
3.1.  Normal mode refinement improves the structure 
3.1.1.  Structure of KvAP-33H1 Fv complex at 3.9 Å resolution 
The diffraction data for the KvAP-33H1 Fv complex contained 16,234 unique 
reflections in the range of 57.89~3.90 Å.  The reported structural model (PDB 
accession code: 2A0L) refined using CNS (113) had 6,740 protein atoms and four 
potassium ions, with Rcryst- and Rfree-factors of 35.8% and 39.2%, respectively (55).  
This model has an average B-factor of 188 Å2, with many atoms reaching over 200 
Å2, indicating an overall high structural flexibility (Figure 3.1a, light line).  Moreover, 
the original structure employed a B-factor cutoff of ~240 Å2, making the B-factors 
for some highly mobile atoms underdetermined. 
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In order to eliminate the differences in R-factors that stemmed from using 
different refinement programs, the normal-mode refinement generally began with a 
re-calculation of the R-factors using the original model as input to REFMAC5 (97).  
The recalculated Rcryst- and Rfree-factors for the KvAP-33H1 Fv complex were 34.9% 
and 37.9%, respectively.  These values were used as reference when comparing with 
the normal-mode refined model.  In order to capture the molecular deformations 
that are intrinsic to this molecule, the tetrameric biological unit was first generated 
from symmetry operations.  The normal-mode calculation was performed on the 
tetrameric biological unit with the best combination of cutoff and stiffness values of 
13 Å and 30, respectively. Only the portion of eigenvectors corresponding to the 
asymmetric unit, which was a half of the tetramer, were used in the normal-mode 
anisotropic B-factor refinement followed by positional refinement using REFMAC5 
(97).  The refinement yielded the lowest Rcryst- and Rfree-factors of 30.0% and 35.0% 
with the inclusion of 48 modes (1203 parameters) (Figure 3.1b; Table 3.1), 
representing decreases of 4.9% in Rcryst-factor and 2.9% in Rfree-factor. It is worth 
noting that the number of thermal parameters used in the normal-mode-based 
anisotropic B-factor refinement is more than five times fewer than in the original 
isotropic B-factor refinement. 
In geometry analysis by MolProbity (114), the residues in the original model 
had a distribution of 77.3% in the Ramachandran favored region and 4.66% in the 
Ramachandran outlier region.  After normal-mode refinement, the distribution 
became 84.5% and 3.03%, respectively, indicating a substantial improvement in 
geometry (Table 3.2). 
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Table 3.1 Statistics of Rcryst- and Rfree-factors after normal-mode refinement 
and subsequent multi-group TLS refinement for all structures 
PDB accession code 2A0L 2BBJ 2PM9 1SUQ 
Initial Rcryst/Rfree 34.9%/37.9% 34.8%/39.5% 23.9%/28.7% 26.0%/31.6% 
NMRef-Rcryst/Rfree  
(number of parameters) 
30.0%/35.0% 
(1203) 
29.6%/35.8% 
(1980) 
22.4%/25.9% 
(42) 
24.0%/29.0% 
(588) 
NMRef+TLS-Rcryst/Rfree 
(number of parameters) 
35.1%/38.2% 
(2260) 
29.3%/34.6% 
(1500) 
21.1%/24.3% 
(600) 
25.5%/29.9% 
(200) 
PDB accession code 2VV5 2AEQ 2INY 2V1C 
Initial Rcryst/Rfree 29.3%/31.2% 28.5%/29.1% 34.4%/43.3% 43.1%/45.7% 
NMRef-Rcryst/Rfree  
(number of parameters) 
26.1%/26.8% 
(147) 
25.0%/27.4% 
(588) 
31.4%/40.1% 
(105) 
28.3%/38.0% 
(63) 
NMRef+TLS-Rcryst/Rfree 
(number of parameters) 
25.8%/26.8% 
(420) 
23.0%/27.0% 
(900) 
32.3%/40.8% 
(200) 
29.1%/37.9% 
(600) 
 
Table 3.2 Comparison of residue distribution in the Ramachandran plot for 
the original models, normal-mode refined models and subsequent multi-
group TLS refinement for all structures 
PDB accession code model Ramachandran Favored (%) Ramachandran Outlier (%) 
2A0L 
Original 77.3 4.66 
NMRef 84.5 3.03 
2BBJ 
Original 90.0 2.30 
NMRef 87.1 2.79 
2PM9 
Original 74.7 8.38 
NMRef 83.7 6.25 
NMRef + TLS 83.8 5.95 
1SUQ 
Original 78.9 4.31 
NMRef 85.5 2.77 
2VV5 
Original 92.4 2.75 
NMRef 93.8 2.35 
NMRef + TLS 94.0 2.35 
2AEQ 
Original 85.9 3.64 
NMRef 88.4 2.64 
NMRef + TLS 89.9 1.82 
2INY 
Original 59.2 14.5 
NMRef 65.5 8.87 
2V1C 
Original 90.8 2.26 
NMRef 77.1 5.33 
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The anisotropic B-factors of the normal-mode model were converted to 
isotropic ones and shown in Figure 3.1a as a dark line, which appeared to be a more 
realistic representation of the thermal motions of a protein at a resolution of 3.9 Å.  
When the ellipsoid of each Cα-atom was mapped to the structure (Figure 3.1c and 
Figure 3.1d), a higher structural flexibility was suggested for the atoms at the 
peripheral region of the structure. 
However, the multi-group TLS refinement using the isotropic-equivalent B-
factor profile from the normal-mode refined structure did not further improve the 
Rcryst- and Rfree-factors (Table 3.1). 
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Figure 3.1 Normal mode refinement of the structure of KvAP-33H1 and Fv 
complex (PDB accession code: 2A0L).  a) B-factor profile for all C atoms in the reported 
structure (light line) and normal-mode refined structure (dark line).  b) The Rcryst- (dashed line) 
and Rfree- (solid line) factors with respect to the number of parameters used in the normal-mode 
refinement.  Original values were plotted as a dashed line and a solid line for Rcryst- and Rfree-
factors, respectively.  c) Ellipsoids for the C atoms captured from the anisotropic thermal 
factors derived from normal-mode refinement for the asymmetric unit.  d) The biological unit 
was shown together with the ellipsoids for the asymmetric unit.  Made with 30% probability.  
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3.1.2.  Structure of the CorA Mg2+ transporter at 3.9 Å resolution 
The reported structure of the CorA Mg2+ transporter (PDB accession code: 
2BBJ) was determined against the diffraction data in the range of 20.0~3.90 Å with 
27,320 unique reflections, and the model contained 13,805 non-hydrogen protein 
atoms (56).  The published structural model had Rcryst- and Rfree-factors of 36.3% 
and 40.6%, respectively.  The average B-factor for the structural model was 163 Å2, 
with an almost flattened B-factor distribution (Figure 3.2a, light line).  Apparently, 
the flexibility of the protein was not appropriately reflected by the modeled B-
factors due to the very low data-to-parameter ratio. 
Prior to the normal-mode refinement, the R-factors for the original PDB 
structure was recalculated using REFMAC5 (97), yielding Rcryst- and Rfree-factors of 
34.8% and 39.5%, respectively.  Since the asymmetric unit of the deposited 
structure of CorA Mg2+ transporter was in a pentameric organization, which is also 
its biological form (56), the normal modes were directly calculated on the pentamer, 
with the optimal combination of the cutoff and stiffness values of 13 Å and 3.  The 
refinement yielded the lowest Rcryst- and Rfree-factors of 29.6% and 35.8% (Figure 
3.2b; Table 3.1).  In relation to the original structure, the Rcryst- and Rfree-factors were 
decreased by 5.2% and 3.7%, respectively.  This improvement was achieved using 
62 modes, equivalent to 1980 thermal parameters that are about 1/7 of the thermal 
parameters used in the original structural refinement. 
The residues in the original model had a distribution of 90.0 and 2.30% in 
the Ramachandran most favored and outlier regions, respectively (56).  For the 
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normal-mode refined model, the distribution became 87.1% and 2.79% in the 
corresponding regions, which is comparable to that of the original model (Table 3.2). 
The B-factor distribution of the normal-mode refined structural model is 
shown in Figure 3.2a (black line).  Mapping it to the structure revealed much 
smaller B-factors for the transmembrane helices and higher B-factors for the 
peripheral region of the cytoplasmic domain (Figure 3.2c and Figure 3.2d), 
consistent with the overall architecture of the transporter. 
Moreover, the multi-group TLS refinement was conducted on the normal-
mode refined structure, and further reduced the Rcryst- and Rfree-factors by 0.3% and 
1.2%, respectively, using 15 groups per chain (1500 parameters) (Table 3.1). 
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Figure 3.2 Normal mode refinement of the structure of CorA Mg2+ transporter 
(PDB accession code: 2BBJ).  a) B-factor profile for all C atoms in the original structure 
(light line) and normal-mode refined structure (black line).  b) The Rcryst- (dashed line) and Rfree- 
(solid line) factors with respect to the number of parameters used in the normal-mode 
refinement. Original values were plotted as a dashed line and a solid line for Rcryst- and Rfree-
factors, respectively.  c) Ellipsoids for the C atoms captured from the anisotropic thermal factor 
derived from normal-mode refinement for the asymmetric unit. d) Ellipsoids for a single chain of 
the homo-pentamer were shown.  Made with 30% probability. 
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3.1.3.  Structure of yeast Sec13/31 vertex element of the COPII vesicular 
coat at 3.3 Å resolution 
The structure of yeast Sec 13/31 vertex element (PDB accession code: 2PM9) 
had 5,170 non-hydrogen protein atoms and 28 water molecule (57).  This structure 
was refined against diffraction data in the range of 40.0~3.30 Å (18,996 unique 
reflections) to obtain Rcryst- and Rfree-factors of 25.1% and 30.5%, respectively.  
Although the average B-factor of the model is 79 Å2, some regions have B-factors of 
over 170 Å2, indicating a rather high local flexibility (Figure 3.3a, light line). 
The original model was input to REFMAC5 (97), yielding Rcryst- and Rfree-
factors of 23.9% and 28.7%, respectively.  The normal-mode calculation was carried 
out on the asymmetric unit that was also its biological form, and the best 
combination of cutoff and stiffness values were 13 Å and 100, respectively.  The 
lowest Rcryst- and Rfree-factors of 22.4% and 25.9% were obtained (Figure 3.3b), 
representing decreases of 1.5% and 2.6% in Rcryst- and Rfree-factors, respectively 
(Table 3.1).  The improvement was achieved using five normal modes (42 
parameters), corresponding to a 100-fold reduction in thermal parameters 
compared with the original structural model. 
The residues in the original model have a distribution of 74.7% and 8.38% in 
the Ramachandran most favored and outlier regions, respectively.  The distribution 
became 83.7% and 6.25% for the residues in the normal-mode refined structure, 
indicating a substantial improvement in geometry over the original model. 
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The isotropic B-factors for each C-atom, converted from the anisotropic B-
factors of the normal-mode model, are shown in Figure 3.3a (dark line).  Mapping 
the anisotropic B-factors on the structure (Figure 3.3c) revealed highly ordered core 
residues and much more mobile regions on the surface of the protein complex. 
The subsequent multi-group TLS refinement on the normal-mode refined 
structure resulted in further improvement.  The lowest Rcryst- and Rfree-factors were 
21.1% and 24.3%, respectively, when each chain was divided into 15 groups (600 
parameters).  These values correspond to decreases of 1.3% and 1.6% in Rcryst- and 
Rfree-factors, respectively.  In addition, the geometry was also improved slightly with 
83.8% and 5.95% of residues in the Ramachandran favored and outlier regions, 
respectively (Table 3.2). 
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Figure 3.3 Normal mode refinement of structure of yeast Sec13/31 vertex 
element of the COPII vesicular coat (PDB accession code: 2PM9).  a) B-factor 
profile for all C atoms in the original structure (light line) and normal-mode refined structure 
(dark line).  b) The Rcryst- (dashed line) and Rfree- (solid line) factors with respect to the number 
of parameters used in the normal-mode refinement. Original values were plotted as a dashed 
line and a solid line for Rcryst- and Rfree-factors, respectively.  c) Ellipsoids for the C atoms 
captured from the anisotropic thermal factor derived from normal-mode refinement for the 
asymmetric unit.  Made with 30% probability. 
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3.1.4. Structure of HIV-1 Reverse transcriptase (RT) in complex with 
Jassen-R185545 at 3.0 Å resolution 
The original structure of HIV-1 RT complex (PDB accession code: 1SUQ) 
contained 8,055 non-hydrogen protein atoms and 29 heterogen atoms, and was 
refined against diffraction data in the range of 19.99~3.0 Å with 28,520 unique 
reflections (58).  The final model was refined using CNS (113) with Rcryst- and Rfree-
factors of 26.2% and 32.5%, respectively.  This structure has an average B-factor of 
84 Å2. However, the large B-factors in some regions (over 100 Å2) indicated a high-
degree local structural flexibility (Figure 3.4a, light line). 
The original model was input to REFMAC5 to recalculate the R-factors, 
yielding Rcryst- and Rfree-factors of 26.0% and 31.6%, respectively.  The normal-mode 
calculation was directly performed on the asymmetric unit, and the optimal 
combination of cutoff and stiffness values were 13 Å and 30.  With the inclusion of 
33 modes (588 parameters), the refinement yielded the lowest Rcryst- and Rfree-
factors of 24.0% and 29.0%, respectively (Figure 3.4b), representing a decrease of 
2.0% in Rcryst-factor and 2.6% in Rfree-factors (Table 3.1). 
The residues of the original structural model had a distribution of 78.9% and 
4.31% in the Ramachandran most favored and outlier regions, respectively.  The 
distribution became 85.5% and 2.77% in corresponding regions for the normal-
mode refined structure, indicating a substantial improvement of geometry over the 
original model (Table 3.2). 
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Overall, the isotropic B-factors converted from the anisotropic B-factors of 
the normal-mode model agreed well with those in the original structure (Figure 3.4a, 
dark line).  However, a number of regions near the surface of the structure (Figure 
3.4c) appeared to be of much higher mobility, consistent with the overall 
architecture of the enzyme. 
In addition, the subsequent multi-group TLS refinement did not further 
improve the refinement (Table 3.1). 
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Figure 3.4 Normal mode refinement of the structure of HIV-1 reverse 
transcriptase (RT) in complex with Jassen-R185545 (PDB accession code: 
1SUQ).  a) B-factor profile for all C atoms in the original structure of HIV-1 Reverse 
transcriptase (RT) in complex with Jassen-R185545 (PDB accession code: 1SUQ) (light line) and 
normal-mode refined structure (dark line).  b) The Rcryst- (dashed line) and Rfree- (solid line) 
factors with respect to the number of parameters used in the normal-mode refinement. Original 
values were plotted as a dashed line and a solid line for Rcryst- and Rfree-factors, respectively.  c) 
Ellipsoids for the C atoms captured from the anisotropic thermal factor derived from normal-
mode refinement for the asymmetric unit.  Made with 50% probability. 
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3.1.5. The open structure of mechanosensitive channel at 3.45 Å resolution 
The crystal structure of mechanosensitive channel MscS in its open form 
(PDB accession code: 2VV5) was determined to 3.45 Å against 46,433 unique 
reflections in the range of 37~3.45 Å (59).  The reported model had 13,692 non-
hydrogen protein atoms, and was refined in REFMAC5 with Rcryst- and Rfree-factors of 
29.3% and 31.2%, respectively.  In the original structure determination, four TLS 
groups, one for TM1 and TM2, one for TM3a and TM3b, one for the first cytoplasmic 
domain and one for the second and third cytoplasmic domains, were used to 
facilitate the refinement.  This system provided a case to test whether the normal-
mode-based refinement is able to further improve TLS-refined structures. 
The original model was first input to REFMAC5 to calculate R-factors, 
yielding Rcryst- and Rfree-factors of 29.3% and 31.2%, respectively, the same as the 
published values.  The normal-mode calculation was directly performed on the 
heptamer in the asymmetric unit, and the optimal combination of cutoff and 
stiffness values were 13 Å and 3.  With the inclusion of 15 modes (147 parameters), 
the normal-mode refinement yielded the lowest Rcryst- and Rfree-factors of 26.1% and 
26.8% (Figure 3.5b), representing decreases of 3.2% and 4.4% in Rcryst- and Rfree-
factor, respectively (Table 3.1), with nearly 100-fold reduction in the number of 
thermal parameters. 
The isotropic B-factor profile converted from the anisotropic one in the 
normal-mode refined model is shown in Figure 3.5a (dark line).  Overall, the 
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normal-mode model appeared to be more reasonable for the resolution of this 
structure (Figure 3.5c and Figure 3.5d). 
The residues in the original structure have a distribution of 92.4% and 2.75% 
in the Ramachandran most-favored and outlier regions, respectively.  For the 
normal-mode refined mode, the distribution became 93.8% and 2.35% in the 
corresponding regions, which is comparable to that of the original model (Table 3.2).  
However, the number of bad contacts decreased to 7 in the normal-mode refined 
model from 37 in the original model, indicating a slight improvement of geometry. 
The subsequent multi-group TLS refinement was carried out based on the 
normal-mode refined model.  When each chain was divided into 3 groups (totally 
420 parameters), the Rcryst-factor was further reduced by 0.3%, while the Rfree-factor 
remained almost the same (Table 3.1).  The distribution in the Ramachandran plot 
of the multi-group TLS-refined model did not differ much from the normal-mode 
refined model (Table 3.2). 
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Figure 3.5 Normal mode refinement of the structure of E.Coli 
mechanosensitive channel MscS (PDB accession code: 2VV5).  a) B-factor profile 
for all C atoms in the original structure (light line) and normal-mode refined structure (black 
line).  b) The Rcryst- (dashed line) and Rfree- (solid line) factors with respect to the number of 
parameters used in the normal-mode refinement. Original values were plotted as a dashed line 
and a solid line for Rcryst- and Rfree-factors, respectively.  c) Ellipsoids for the C atoms captured 
from the anisotropic thermal factor derived from normal-mode refinement for the asymmetric 
unit.  d) Ellipsoids on a single chain of the homo-heptamer.  Made with 50% probability. 
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3.1.6. Structure of influenza virus neuraminidase complexed with its 
antibody at 3.0 Å resolution 
The structure of influenza virus neuraminidase complexed with its antibody 
was determined to 3.0 Å resolution from diffraction data collected at room 
temperature (22 oC) (PDB accession code: 2AEQ) (60).  The diffraction data had a 
total of 23,223 unique reflections, just about four times the total of non-hydrogen 
atoms in the final structural model (4760 protein atoms and 142 heterogen atoms).  
Probably to improve the data-to-parameter ratio, the model was refined using CNS 
(113) with a constant isotropic B-factor of 32.64 Å2 for all atoms and had Rcryst- and 
Rfree-factors of 26.7% and 31.2%, respectively (Figure 3.6a, light line). 
The structural model was first input to REFMAC5, yielding Rcryst- and Rfree-
factors of 28.5% and 29.1%, respectively (Table 3.1).  Although neuraminidase is 
naturally a homotetramer, there is only one monomer in the asymmetric unit of this 
structure.  Thus, normal-mode calculations were performed on the tetramer with 
the optimal combination of cutoff distance of 13 Å and stiffness of 3.  The plot of 
Rcryst- and Rfree-factors as a function of the number of parameters used in the 
refinement suggested that inclusion of 33 modes (totally 588 parameters) resulted 
in the lowest Rcryst-  and Rfree -factors (24.5% and 27.4%, respectively) (Figure 3.6b).  
This represents decreases of 4.0% and 1.7% in Rcryst- and Rfree-factors, respectively, 
achieved by using ~10-fold fewer thermal parameters than in the original structural 
refinement (Table 3.1). 
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In the Ramachandran plot, the original model had 85.9% and 3.64% residues 
in the Ramachandran most favored and outlier regions, respectively.  The normal-
mode-refined structural model had a slightly improved geometry, with 88.4% and 
2.64% of the residues in these regions, respectively (Table 3.2). 
A second structure of neuraminidase was also reported, which was 
determined from a frozen crystal but otherwise the same sample at 2.1 Å resolution 
(PDB accession code: 2AEP) (60).  As a way to compare, Fig.6a shows the isotropic-
equivalent B-factors for C-atoms in the normal-mode refined structure, the 
constant B-factors in the original structure (PDB accession code: 2AEQ) at 3.0 Å 
resolution, and the isotropic B-factors in the 2.1 Å structure (PDB accession code: 
2AEP).  It is clear that the profile of B-factor in the normal-mode refined structure 
matches with that of the 2.1 Å structure very well; however, higher absolute values, 
consistent with its lower resolution, were observed.  Thus, it is evident that the 
normal-mode refinement delivers a reasonable B-factor profile for 2AEQ that is 
otherwise not practical in conventional refinement.  In addition, the ellipsoids 
mapped to the structure revealed higher structural flexibility for the outer regions 
of the tetrameric structure, as expected for protein structures (Figure 3.6c and 
Figure 3.6d). 
With the B-factor profile in the normal-mode refined structure, automated 
multi-group TLS refinement was conducted to see if further decreases in R-factors 
can be achieved.  Indeed, the Rcryst- and Rfree-factors were further reduced by 1.5% 
and 0.4% using 15 groups per chain (equals to 900 parameters) (Table 3.1).  
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Moreover, the normal-mode and TLS model had a distribution as 89.9% and 1.82% 
in the Ramachandran favored and outlier regions, respectively, indicating a slight 
further improvement of the geometry. 
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Figure 3.6 Normal mode refinement of the structure of influenza virus 
neuraminidase and its antibody (PDB accession code: 2AEQ).  a) B-factor profile 
for all C atoms in the original structure (dashed line), its high-resolution structure (PDB 
acession code: 2AEP) (light solid line), and normal-mode refined structure (dark line).  b) The 
Rcryst- (dashed line) and Rfree- (solid line) factors with respect to the number of parameters used 
in the normal-mode refinement.  Original values were plotted as a dashed line and a solid line 
for Rcryst- and Rfree-factors, respectively.  c) Ellipsoids for the C atoms captured from the 
anisotropic thermal factor derived from normal-mode refinement for the asymmetric unit.  d) 
The biological unit was shown together with the ellipsoids for the asymmetric unit.  Made with 
50% probability. 
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3.1.7.  Structure of chicken embryo lethal orphan adenovirus major coat 
protein, hexon at 3.9 Å resolution 
The reported model of hexon (PDB accession code: 2INY) had Rcryst- and Rfree-
factors refined in CNS of 37.2% and 41.6%, respectively (61).  The diffraction data in 
the range of 47.06 ~ 3.90 Å had 14,124 unique reflections, whereas the final 
structural model had 7,523 non-hydrogen protein atoms.  Thus, the data-to-
parameter ratio was rather low.  Possibly for this reason, the structure was refined 
by constraining all B-factors to 30.0 Å2 (Figure 3.7a, light line).  According to the 
authors, various efforts were made to further refine the structure, but all proved 
futile. 
Prior to normal-mode based refinement, the R-factors for the original model 
were recalculated using REFMAC5, yielding Rcryst- and Rfree-factors of 34.4% and 
43.3%, respectively.  The normal-mode calculation was performed on the trimeric 
biological unit, and the optimal combination of the cutoff distance and stiffness 
values were 20 Å and 3.  Only the portion of eigenvectors corresponding to the 
monomeric asymmetric unit was included in normal-mode refinement (Figure 3.7b).  
With the inclusion of 12 modes (105 parameters), the refinement yielded the lowest 
Rcryst- and Rfree-factors of 31.4% and 40.1%, representing decreases of 3.0% and 3.2% 
in Rcryst- and Rfree-factors, respectively.  The improvement was achieved by using 70-
fold fewer thermal parameters than in the original structural refinement. 
The residues in the original model had a distribution of 59.2% and 14.5% in 
the Ramachandran most favored and outlier regions, respectively.  After normal-
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mode refinement, the distribution became 65.5% and 8.87% in corresponding 
regions, indicating a substantial improvement in geometry over the original model 
(Table 3.2). 
The isotropic B-factors converted from the anisotropic B-factors in the 
normal-mode refined model were compared with those of the original model in 
Figure 3.7a (dark line).  Although the majority of the structure has a rather low B-
factor, there are a number of regions of extremely high mobility (Figure 3.7a).  As 
expected, these regions are located far away from other structural components in 
native trimeric structure (Figure 3.7c and Figure 3.7d). 
However, the subsequent multi-group TLS refinement on the normal-model 
refined structure did not result in further decreases in R-factors (Table 3.1).  Thus, 
in this case, no gain was obtained by further applying TLS refinement. 
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Figure 3.7 Normal mode refinement of the structure of the chicken embryo 
lethal orphan adenovirus major coat protein (PDB accession code: 2INY).  a) B-
factor profile for all C atoms in the original structure (light line) and normal-mode refined 
structure (dark line).  b) The Rcryst- (dashed line) and Rfree- (solid line) factors with respect to the 
number of parameters used in the normal-mode refinement.  Original values were plotted as a 
dashed line and a solid line for Rcryst- and Rfree-factors, respectively.  c) Ellipsoids for the C 
atoms captured from the anisotropic thermal factor derived from normal-mode refinement for 
the asymmetric unit.  d) The biological unit was shown together with the ellipsoids for the 
asymmetric unit.  Made with 50% probability. 
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3.1.8.  Structure of Deinococcus radiodurans RecR and RecO (drRecOR) at 
3.8 Å resolution 
The original structural model of drRecOR (PDB accession code: 2V1C) had a 
total of 4,778 non-hydrogen protein atoms and three zinc atoms, and was refined 
against the diffraction data in the range of 3.80~71.25 Å (with 6,850 unique 
reflections) (62).  Due to the very low data-to-parameter-ratio, the reported 
refinement was terminated after a single round of rigid-body refinement and 
manual rebuilding with Rcryst- and Rfree-factors of 45.8% and 44.3%, respectively.  
The final model has a constant B-factor of 96 Å2 (Figure 3.8a, light line). 
Prior to the normal-mode based refinement, the original model was input to 
REFMAC5, yielding Rcryst- and Rfree-factors of 43.1% and 45.7%, respectively.  The 
normal-mode calculation was performed on the dimeric biologic unit and the best 
combination of cutoff and stiffness values were 13 Å and 100.  The portion of 
eigenvectors corresponding to the monomeric asymmetric unit was included in the 
normal-mode refinement using a different number of normal modes (Figure 3.8b).  
The lowest Rcryst- and Rfree-factors were 28.2% and 38.0%, respectively, when the 
eight lowest normal modes (equivalent to 63 thermal parameters) were used.  
Compared with the original model, this result represents decreases of 14.9% and 7.7% 
in Rcryst- and Rfree-factors, respectively. 
The residues in the original model are distributed with 90.8% and 2.26% in 
the Ramachandran most favored and outlier regions, respectively.  The distribution 
became 77.1% and 5.33%, respectively, for the normal-mode-refined structure.  
63 
 
 
This result  may be ascribed to the fact, at least in part, that the original model for 
drRecOR was constructed based on the structures of drRecO and drRecR 
determined at much higher resolution without further positional refinement.  
However, the number of bad contacts decreased to 23 in the normal-mode refined 
structure from 58 in the original model. 
The B-factors from the normal-mode refined model (Figure 3.8a) suggest 
realistic flexibility variations along the structure, with more ordered region inside 
and more flexible regions outside (Figure 3.8c and Figure 3.8d). 
In addition, the subsequent multi-group TLS refinement on the normal-mode 
refined structure did not make any remarkable improvement.  Although the Rfree-
factor was decreased to 37.9% with 10 TLS groups per chain, the Rcryst-factor was 
increased to 29.1% (Table 3.1). 
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Figure 3.8 Normal mode refinement of the structure Deinococcus radiodurans 
RecR and RecO (PDB accession code: 2V1C).  a) B-factor profile for all C atoms in the 
original structure of (light line) and normal-mode refined structure (dark line).  b) The Rcryst- 
(dashed line) and Rfree- (solid line) factors with respect to the number of parameters used in the 
normal-mode refinement.  Original values were plotted as a dashed line and a solid line for Rcryst- 
and Rfree-factors, respectively.  c) Ellipsoids for the C atoms captured from the anisotropic 
thermal factor derived from normal-mode refinement for the asymmetric unit.  d) The biological 
unit was shown together with the ellipsoids for the asymmetric unit.  Made with 50% 
probability. 
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3.2.  Role of Phe95Tyr mutation in binding affinity of BHA 
3.2.1.  Expression of recombinant wild-type and mutant BHA glycoproteins 
The recombinant wild-type BHA and its mutants (single mutants: 
Phe95Tyr, Asn194Asp and double mutant Phe95Tyr/Asn194Asp) were 
expressed in mammalian cells CV-1 using vaccinia viral system (kindly provided by 
Dr. Bernard Moss) (98) and purified to high purity (see Materials and Methods).  For 
the Asn194Asp and Phe95Tyr/Asn194Asp mutants, the glycosylation site 
was depleted in order to mimic the situation in which influenza BHA lost its 
glycosylation site at this position in some field isolates (79, 80) or due to egg 
adaptation (72–78).  Consequently, the molecular weights of the HA0 monomer for 
these two mutants were about three kilo-daltons smaller than that of wild-type BHA 
as shown on the SDS-PAGE (Figure 3.9). 
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Figure 3.9 SDS-PAGE analysis of recombinant wild type BHA and its mutants.  
Shown are wild type BHA (1), mutant Phe95Tyr (2),  Asn194Asp (3) and 
Phe95Tyr/ Asn194Asp (4).  (A) Recombinant proteins after gel filtration 
purification.  (B) Purified proteins after treatment with PNGase F to remove the 
glycans. 
3.2.2.  The mutation Phe95Tyr universally enhanced the binding affinity 
of BHA 
To investigate the impact of Phe95Tyr mutation on the receptor binding 
capability of BHA, a glycan microarray analysis on wild-type BHA and each of its 
mutants (Figure 3.10) is carried out.  Out of the more than 400 glycans on the 
microarray chips, a total of 97 glycans showed significant binding in at least one of 
the four protein samples (wild-type BHA and its mutants) (Table 3.3).  The 
fluorescence intensity is shown for each of these glycans for each of the tested 
proteins in Figure 3.10A~D in which the glycans are grouped according to the 
presence or absence of a terminal sialic acid group and the linkage between the 
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sialic acid group.  Clearly for wild-type BHA, it has an overall weak binding for the 
majority of glycans, although it does exhibit a preference towards (2,6)-linked 
human-like receptor analogs (red in Figure 3.10), consistent with the abundance 
of(2,6)-linked sialic acids in human upper respiratory tract where the wild-type 
influenza B virus infects its human host.  Along the same line, the mutant 
Asn194Asp, which causes the loss of a glycosylation site at HA1 194~196, as 
frequently found in egg-adapted variants (72–78), resulted in a preferential binding 
to (2, 3)-linked avian-like glycan, and the overall fluorescence intensity is 
substantially increased compared to the wild-type BHA. 
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Figure 3.10 The mutation Phe95Tyr promotes the binding of BHA to 
synthetic glycans in glycan array assays.  The results of glycan array assays are shown 
for (A) wild type, (B) mutant Phe95Tyr; (C) mutant Asn194Asp; and (D) mutant 
Phe95Tyr/Asn194Asp.  Please refer to Table 3.3 for the full name of each glycan.  The 
glycans are categorized into 2-3-linked sialosides (■), glycans containing both 2-3 and 2-6 
sialosides (■)2-6-linked sialosides (■), free sialic acid (■) and others (■). 
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Table 3.3 Full names for the glycans of which the relative fluorescence unit 
(RFU) are above 5000 
glycan 
array 
Glycan Structure 
1 Fucα1-2[6OSO3]Galβ1-4[6OSO3]Glc-Sp0 
2 Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ-Sp10 
3 Neu5Acα2-8Neu5Acα2-8Neu5Acα-Sp8 
4 Galβ1-4GlcNAcβ1-2Manα-Sp0 
5 GlcNAcα1-4Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
6 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 
7 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp9 
8 Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 
9 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc-Sp0 
10 Neu5Acα2-3Galβ1-3GalNAcα-Sp8 
11 Neu5Acα2-3Galβ1-3GalNAcα-Sp14 
12 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp0 
13 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp8 
14 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 
15 Neu5Acα2-3(Neu5Acα2-3Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ-Sp0 
16 Neu5Acα2-3GalNAcα-Sp8 
17 Neu5Acα2-3GalNAcβ1-4GlcNAcβ-Sp0 
18 Neu5Acα2-3Galβ1-3[6OSO3]GlcNAc-Sp8 
19 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp8 
20 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
21 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ-Sp8 
22 Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα-Sp8 
23 Neu5Acα2-3Galβ-Sp8 
24 Neu5Acα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp0 
25 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 
26 Neu5Acα2-3Galβ1-3GlcNAcβ-Sp0 
27 Neu5Acα2-3Galβ1-3GlcNAcβ-Sp8 
28 Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ-Sp8 
29 Neu5Acα2-3Galβ1-4(Fucα1-3)[6OSO3]GlcNAcβ-Sp8 
30 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
31 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
32 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp8 
33 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ-Sp8 
34 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 
35 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 
36 Neu5Acα2-3Galβ1-4GlcNAcβ-Sp0 
37 Neu5Acα2-3Galβ1-4GlcNAcβ-Sp8 
38 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 
39 Neu5Acα2-3Galβ1-4Glcβ-Sp0 
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40 Neu5Acα2-3Galβ1-4Glcβ-Sp8 
41 Galβ1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-6)GalNAcα-Sp14 
42 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 
43 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 
44 Galβ1-3(Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6)GalNAcα-Sp14 
45 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-6)GalNAcα-Sp14 
46 
Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp12 
47 Neu5Ac(9Ac)a2-3Galβ1-4GlcNAcβ-Sp0 
48 Neu5Ac(9Ac)a2-3Galβ1-3GlcNAcβ-Sp0 
49 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 
50 Neu5Acα2-3-Galβ1-3(Galβ1-4(Fucα1-3)GlcNAcβ1-6)GalNAc-Sp14 
51 Neu5Acα2-3Galβ1-4GlcNAcβ1-3GalNAc-Sp14 
52 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3GalNAcα-Sp14 
53 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ1-3GalNAcα-Sp14 
54 Neu5Acα2-3Galβ1-3GlcNAcβ1-3GalNAcα-Sp14 
55 Neu5Acα2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glcβ-Sp0 
56 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ-Sp8 
57 Neu5Gcα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 
58 Neu5Gcα2-3Galβ1-3GlcNAcβ-Sp0 
59 Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
60 Neu5Gcα2-3Galβ1-4GlcNAcβ-Sp0 
61 Neu5Gcα2-3Galβ1-4Glcβ-Sp0 
62 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-Sp8 
63 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-Sp14 
64 
Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp12 
65 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp12 
66 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
N(LT)AVL 
67 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp8 
68 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp12 
69 
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-
Sp13 
70 Neu5Acα2-6GalNAcα-Sp8 
71 Neu5Acα2-6GalNAcβ1-4GlcNAcβ-Sp0 
72 Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ-Sp8 
73 Neu5Acα2-6Galβ1-4GlcNAcβ-Sp0 
74 Neu5Acα2-6Galβ1-4GlcNAcβ-Sp8 
75 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 
76 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 
77 Neu5Acα2-6Galβ1-4Glcβ-Sp0 
78 Neu5Acα2-6Galβ1-4Glcβ-Sp8 
79 Neu5Acα2-6Galβ-Sp8 
80 Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp12 
81 GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp12 
82 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp12 
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83 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp12 
84 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 
85 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 
86 Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc-Sp12 
87 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc-Sp12 
88 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcNAcβ1-4GlcNAc-Sp12 
89 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3Manβ1-4GlcNAcβ1-4GlcNAc-Sp12 
90 Neu5Acα2-6GlcNAcβ1-4GlcNAc-Sp21 
91 Neu5Acα2-6GlcNAcβ1-4GlcNAcβ1-4GlcNAc-Sp21 
92 Neu5Acα2-6Galβ1-4GlcNAcβ1-3GalNAc-Sp14 
93 Neu5Acα2-6Galβ1-3GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-4Glc-Sp21 
94 Neu5Acα2-6Galβ1-4GlcNAcβ1-6(Fucα1-2Galβ1-3GlcNAcβ1-3)Galβ-4Glc-Sp21 
95 Neu5Gcα2-6Galβ1-4GlcNAcβ-Sp0 
96 Neu5Acα-Sp11 
97 Neu5Acα-Sp8 
Sp0 CH2CH2NH2 
Sp8 CH2CH2CH2NH2 
Sp9 CH2CH2CH2CH2CH2NH2 
Sp10 NHCOCH2NH 
Sp11 OCH2C6H4-p-NHCOCH2NH 
Sp12 Asparagine 
Sp13 Glycine 
Sp14 Threonine 
Sp15 Serine 
Sp16 PNP (OC6H4NH2) 
Sp17 OCH2C6H4NH2 
Sp18 O(CH2)3NHCO(CH2)5NH2 
Sp19 EN or NK 
Sp20 GENR 
Sp21 N(CH3)-O-(CH2)2-NH2 
Sp22 NST 
MDPLy
s 
Mur-L-Ala-D-iGlnb-(CH2)4NH2 
The color scheme used here is the same as that in Figure 3.10. The glycans are 
categorized into (2,3)-linked sialosides (■), glycans containing both (2,3) and (2,6) 
sialosides (■), (2,3)-linked sialosides (■), free sialic acid (■) and others (■). The linker 
structures are also listed at the end of the table. 
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Compared to the wild-type BHA, although Phe95Tyr BHA shares the same 
preference for (2,6)-linked human-like receptors (Figure 3.10B), the fluorescence 
intensity is significantly improved for (2,3)-linked avian-like receptors (in green 
color), (2,6)-linked human-like receptors (in red color), (2,3)/(2,6)-linked 
receptors (in blue color) and free sialic acids (in black color).  Similarly, compared to 
Asn194Asp, the Phe95Tyr/Asn194Asp mutant has significantly enhanced 
binding to all types of sialic-acid-containing receptors (Figure 3.10D).  In addition, it 
is noteworthy that Phe95Tyr/Asn194Asp exhibited higher binding even for 
several glycans that do not contain sialic acid moiety (Table 3.3). 
In order to quantify the impact of Phe95Tyr mutation on the binding 
affinity of BHA, dose-dependent glycan binding assays using (2,3)-linked avian-like 
receptor and (2,6)-linked human-like receptor are performed  (Table 3.4).  Wild-
type BHA preferentially binds to the (2,6)-linked human-like receptor 6’SLN-LN.  
The mutation Phe95Tyr simultaneously enhanced the binding for both avian-like 
and human-like receptors, 3’SLN-LN and 6’SLN-LN (Table 3.4).  The calculated 
apparent binding constants for wild-type and Phe95Tyr BHA were 5.0±4.2  10-3 
M and 1.3±0.4  10-6 M for the 3’SLN-LN receptor, 1.5±0.8  10-4 M and 1.1±0.7  10-
11 M for the 6’SLN-LN receptor, respectively (Table 3.4), representing an 103 and 107 
increase in binding affinity as the result of Phe95Tyr for 3’SLN-LN and 6’SLN-LN 
receptors.  Not surprisingly, the mutation Asn194Asp, which causes the loss of a 
glycosylation site at HA1 194~196, as frequently found in egg-adapted variants (72–
78), resulted in  preferential binding to (2,3)-linked avian-like receptor, with an 
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apparent binding constant of 3.0±1.1  10-12 M for 3’SLN-LN, in contrast to the 
6.0±0.9  10-5 M binding constant for (2,6)-linked 6’SLN-LN (Table 3.4).  As seen 
for the single Phe95Tyr mutant, the double mutant Phe95Tyr/Asn194Asp 
improved the binding for both (2,3)-linked and (2,6)-linked receptors, with 
apparent binding constants of 7.6±0.9  10-12 M and 2.7±0.9  10-12 M for 3’SLN-LN 
and 6’SLN-LN, respectively (Table 3.4).  This corresponded to an increase of about 
107 times in binding affinity towards human receptor analog by the Phe95Tyr 
mutation when BHA does not have a glycosylation at HA1 194~196.  Thus, 
regardless of whether or not there is a glycosylation at HA1 194~196, the mutation 
Phe95Tyr enhances the binding of BHA for both avian and human-like receptors 
to a comparable affinity, resulting in minimal discrimination. 
Table 3.4 Equilibrium dissociation constants of recombinant wild-type BHA 
protein and its mutants in binding to (2,3) and (2,6)-linked receptor 
analogs 
BHA 
3'SLN-LN* 
n Kd’ R
2
 
Wild type 0.490.05 5.04.2×10
-3
 M 0.970.01 
Phe95Tyr 0.900.01 1.30.4×10
-6
 M 0.9940.003 
Asn194Asp 1.500.02 3.01.1×10
-12
 M 0.9970.001 
Phe95Tyr/Asn194Asp 1.310.01 7.60.9×10
-12
 M 0.9940.001 
BHA 
6'SLN-LN* 
n Kd’ R
2
 
Wild type 0.610.03 1.50.8×10
-4
 M 0.960.01 
Phe95Tyr 1.270.03 1.10.7×10
-11
 M 0.9950.001 
Asn194Asp 0.810.07 6.00.9×10
-5
 M 0.9870.001 
Phe95Tyr/Asn194Asp 1.630.02 2.70.9×10
-12
 M 0.9700.001 
* The apparent binding constant (Kd’), co-cooperativity factor (n) and R-square (R2) by 
fitting the data to the linearized Hill equation in order to quantitatively determine the relative 
binding affinities of BHAs, and their absolute values should be compared only in this context. 
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3.2.3.  Results of red blood cells binding assay 
Red blood cells from different species are known to contain varying amounts 
of avian and/or human-like receptors.  Thus, if the enhanced binding affinity of 
Phe95Tyr for synthetic receptors holds true, it is expected that this mutation 
allows better binding for natural sialic acid receptors on many different red blood 
cell types.  As shown in Figure 3.11, the big circles are Nickel-NTA agarose beads, 
the black dots are red blood cells.  The wild type BHA protein is coated on the 
agarose beads through its His-tag binding to the Ni-NTA.  If wild type BHA binds the 
receptors on RBC, the agarose bead (big circle) is surrounded by a layer of RBCs 
(black dots).  One thing needed to be noted is that the quality of the agarose beads 
might also contribute to the heterogeneity of beads, where some beads are bare and 
some beads are coated with red blood cells. 
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Figure 3.11 Human red blood cell (RBC) binding with wild type BHA.  The big 
circles are Nickel-NTA agarose beads, the black dots are red blood cells.  The BHA protein is 
coated on the agarose beads through its His-tag binding to the Ni-NTA.  If BHA binds the 
receptors on RBC, the agarose bead (big circle) is surrounded by a layer of RBCs (black dots). 
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Red blood cells from eight species were tested (Figure 3.12).  All four 
proteins were found to bind well to human red blood cells.  Compared with their 
corresponding wild-type proteins, both Phe95Tyr and Phe95Tyr/Asn194Asp 
mutants bound significantly better for red blood cells from chicken, turkey, and 
guinea pig, and somewhat better for those from rabbit and bovine.  For the red 
blood cells from swine, the mutant Phe95Tyr bound significantly better while 
Phe95Tyr/Asn194Asp only bound slightly better than their corresponding 
wild-type proteins (Figure 3.12).  Therefore, the higher binding affinity of the 
Phe95Tyr and Phe95Tyr/Asn194Asp mutants for synthetic receptors can be 
readily translated into a much stronger binding to natural sialic acid receptors on 
red blood cells. 
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Figure 3.12 Red blood cell (RBC) bindging assay.  The species of RBC are listed on the 
left. 
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3.2.4.  The mutation Phe95Tyr competitively blocked the binding and 
infection of influenza A virus 
Since binding to cell-surface receptors is a prerequisite for infecting host 
cells by influenza virus, the key question is whether the much higher binding affinity 
of the Phe95Tyr and Phe95Tyr/Asn194Asp mutants would allow them to 
compete more effectively against infection caused by influenza virus.  As a stringent 
test, influenza A/H3N2 virus that generally has a much higher binding affinity for 
cell-surface receptors than influenza B virus was used [19], an 
A/Brisbane/10/2007-like isolate TX-419 (H3N2) strain that was kindly provided by  
Dr. Pedro Piedra.  The test also included a “blank” where no influenza A virus was 
added and a “positive control” where only influenza A virus was added (Figure 3.13).  
If the binding affinity of BHA and/or its mutants is strong enough to compete 
against influenza A virus for binding to cultured cells, it is expected to see a lower 
virus titer in the presence of these recombinant proteins.  Madin Darby Canine 
Kidney (MDCK) was used for the assay.  Using five hemagglutination units (HAU) of 
influenza A virus as input to infect MDCK cells, at 24 hour post-infection, the 
“positive control” had a virus titer of about 32 HAU per 50 L 1% human red blood 
cells.  With 400 g recombinant proteins, the wild type had about two-fold 
inhibition of influenza A virus over the “positive control” (Figure 3.13), whereas the 
Phe95Tyr mutant displayed eight-fold inhibition, representing four-times 
stronger inhibition.  Most strikingly, while the Asn194Asp single mutant exhibited 
a very weak inhibition against the binding of influenza A virus, the mutant 
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Phe95Tyr/Asn194Asp completely blocked the infection of influenza A virus, 
with as low as 100 g (Figure 3.13) recombinant proteins.  In conclusion, the higher 
binding affinity of the Phe95Tyr and Phe95Tyr/Asn194Asp mutants for 
synthetic and natural sialic acid receptors allows a much stronger competition 
against influenza A virus infection. 
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Figure 3.13 The mutation Phe95Tyr efficiently inhibits the binding of 
influenza A virus to MDCK cells.  The “Blank” sample is the negative control where the 
MDCK cells grow under normal condition in the binding inhibition assay. The “Positive” sample 
is where MDCK cells are infected with 5 HAU influenza A virus. The “Wild type” and 
“Phe95Tyr” samples represent those wells where the MDCK cells are first exposed to 400 g 
wild type BHA or Phe95Tyr mutant before infection by 5 HAU influenza A viral particles. The 
“Asn194Asp” and “Phe95Tyr/Asn194Asp” samples are for those wells where the MDCK 
cells are first bound to 200 g Asn194Asp or Phe95Tyr/Asn194Asp mutants before the 
infection of 5 HAU influenza A virus. The supernatants after 24-hour incubation are used for the 
hemagglutination assay (upper Fig.). If there are enough viruses at a specific dilution, the lattice 
will form due to the interactions (agglutination) between RBC and hemagglutinin on the surface 
of influenza A viruses (shown as pink circle); otherwise, the RBC will settle to the bottom of the 
well to form a red button (shown as a small red circle in a big pink circle). The titer is read as the 
endpoint of agglutination (lower Figure). The titers are much smaller if Phe95 is mutated to 
Tyr95 as shown by comparing Phe95Tyr with wild type or Phe95Tyr/Asn194Asp with 
Asn194Asp, meaning that the virus could not grow well if Phe95Tyr or 
Phe95Tyr/Asn194Asp is present. The results indicate that the Phe95Tyr and 
Phe95Tyr/Asn194Asp mutants could compete against the hemagglutinins on the influenza 
A virus in the binding to the receptors on the MDCK cells, thus inhibiting the entrance of 
influenza A virus. 
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3.2.5.  The mutation Phe95Tyr greatly improved the binding of BHA to 
three cultured cell lines 
Based on the results of the influenza virus infection inhibition assay 
presented above, the following question was that whether the enhanced receptor-
binding affinity of the Phe95Tyr and Phe95Tyr/Asn194Asp mutants allows 
BHA to bind host cells significantly better.  A whole-cell-based ELISA assay was used 
to quantitatively measure the amount of BHA proteins immobilized on cell culture 
monolayers due to their association with cell-surface receptors (see Materials and 
Methods for details).  Three established cell lines were used: MDCK, Baby hamster 
kidney (BHK21), and African green monkey kidney (Vero) (115).  Compared to the 
parental MDCK cells, BHK21 cells has a substantially lower level of (2,6)-linked 
human-like receptors on the cell surface and supports poorly the growth of 
influenza A and B viruses (116, 117).  Overall, the wild-type BHA exhibited very 
weak binding to all three cell lines, with the weakest for BHK21 cell line (Figure 
3.14A).  The mutation Phe95Tyr substantially improved the binding to all these 
cell lines, and the most significant improvement was seen for the Vero cell line 
(Figure 3.14B).  The Asn194Asp mutant had a similar binding affinity as the 
Phe95Tyr on the wild-type background (Figure 3.14C), whereas the 
Phe95Tyr/Asn194Asp double mutant substantially enhanced the binding over 
those of Asn194Asp (Figure 3.14D).  Taken together, the mutation Phe95Tyr 
allowed for much tighter binding to all the three cell lines tested here.  
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Figure 3.14 The mutation Phe95Tyr enhances the binding of BHA to the 
surface of cultured cells.  The binding signals are expressed as the percentage of the 
maximum chemiluminescence intensity for MDCK (A), BHK21 (B) and Vero (C) in cell-based 
ELISA. In all three cell lines tested, wild-type BHA has the weakest binding, whereas the 
Phe95Tyr/Asn194Asp mutant shows the strongest binding. 
3.2.6.  Replication of recombinant influenza B viruses in MDCK cells and 
mice 
In the process of infecting hosts, the hemagglutinin protein of influenza virus 
carries out the following principal functions: binding to cell-surface receptors, 
signaling endocytosis, and mediating membrane fusion and release of viral genetic 
materials.  In order to ascertain the functions of BHA harboring the introduced 
Phe95Tyr mutation, recombinant influenza B viruses were generated by reverse 
genetics using all genes from influenza B/Lee/40 (generous gifts from Dr. Kawaoka) 
following previously reported protocols (103).  The mutations at amino acid sites 95 
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and 194 in BHA were introduced into the coding region of B/Lee/40 HA by site-
directed mutagenesis using Quikchange kit (Agilent).  All the viruses have the 
designed sequences after one passage in MDCK cells.  However, in wild-type 
recombinant B/Lee/40 virus, Asn194 was mutated to Asp194 or Ser194 after the 
second passage in MDCK cells.  Because Asn194 was not stable in MDCK cells in 
wild-type recombinant B/Lee/40 virus, the studies were only conducted on 
recombinant B/Lee/40 viruses harboring Asn194Asp or 
Phe95Tyr/Asn194Asp in BHA.  
From the data in Table 3.5, by comparing to the titer of Asn194Asp virus 
(at 2.8106 pfu/mL), which can be deemed as an egg-adapted wild-type virus, the 
Phe95Tyr/Asn194Asp virus had a comparable titer of 3.0106 pfu/ml when 
replicated in MDCK cells.  However, the Phe95Tyr/Asn194Asp virus was 
attenuated by ~1,000-fold when it was replicated in mouse lung.  
Table 3.5 Replication capabilities of recombinant viruses. 
 
a MDCK cells were infected at MOI of 0.1, and the titer was determined at 48 hours post-
infection.  b Mice were administered viruses intranasally at 104 PFU, and lungs were harvested at 
3 days postinfection. Titers are expressed as pfu per ml lung supernatant. 
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3.2.7.  Agglutination of erythrocytes by recombinant viruses 
The ability of recombinant viruses to agglutinate erythrocytes of different 
animal species was examined (Table 3.6). Chicken, turkey and guinea pig 
erythrocytes contain mixtures of (2,3)- and (2,6)-linked sialic acid, whereas 
sheep, horse and bovine erythrocytes contain mainly (2,3)-linked sialic acid (118, 
119).  Not only the link type of the sialic acid, but also the density and distribution of 
the receptor affect the agglutination reaction. The Asn194Asp virus agglutinates 
erythrocytes from all species of animals tested but show higher HA titers against 
erythrocytes bearing both (2,3)- and (2,6)-linked sialic acid when the reactions 
are incubated at 4 degree for 2 h. After further incubation at 37 ℃ for 2h when 
neuraminidase on the virus begins to cleave the sialic acid bound by BHA, the 
Asn194Asp virus could only agglutinate turkey erythrocytes. With incubation at 
37 degree overnight, all Asn194Asp viruses are released from turkey erythrocytes. 
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Table 3.6 Agglutination of erythrocytes by recombinant viruses under 
different conditionsa 
Erythrocytes
b
 
Agglutination by virus (HAU/50 l) 
4 ℃, 2h 
4 ℃, 2h and 
37 ℃, 2h 
4 ℃, 2h and 
37 ℃, overnight 
 Asn194Asp Phe95Tyr/Asn194Asp Asn194Asp Phe95Tyr/Asn194Asp Asn194Asp Phe95Tyr/Asn194Asp 
cRBC 128~256 8~16 <2 8~16 <2 <2 
tRBC 256~512 16~32 128~256 16~32 <2 2~4 
gpRBC 128~258 16~32 <2 16~32 <2 16~32 
sRBC 64~128 64~128 <2 32~64 <2 <2 
hoRBC 4~8 64~128 <2 64~128 <2 32~64 
bRBC 64~128 16~32 <2 16~32 <2 <2 
Asialo RBC <2 <2 <2 <2 <2 <2 
aHAU were recorded at different time points after erythrocytes were incubated with 
virus for 2 h at 4℃, then placed at 37 ℃ for 2 h, and overnight.  bcRBC, chicken red blood cell 
(RBC); tRBC, turkey RBC; gpRBC, guinea pig RBC; sRBC, sheep RBC; hoRBC, horse RBC; bRBC, 
bovine RBC. Asialo chicken RBCs were produced by cleaving sialic acid with Clostridium 
perfringens neuraminidase prior to the agglutination assay. 
 
In contrast, the Phe95Tyr/Asn194Asp virus displays relatively higher 
HA titers against erythrocytes containing (2,3)-linked sialic acid with the reactions 
incubated at 4 degree for 2h. After incubation at 37 degree for 2h, the HA titers of 
the Phe95Tyr/Asn194Asp virus against erythrocytes from five species remains 
same. Even after overnight incubation at 37 degree, this virus still agglutinates 
turkey, guinea pig and horse erythrocytes with same or lower HA titers. 
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3.2.8.  Cell surface binding of recombinant viruses 
The binding of recombinant viruses to the cell surface will directly reflect the 
ability of the virus to infect the cell. In order to measure this interaction, the 
fluorescently labeled viruses were added to the pre-chilled cell monolayer. The low 
temperature will prevent the endocytosis of bound virions.  Four different cell lines 
were used including BHK21, Vero, A549 (human alveolar basal epithelial cells) and 
MDCK (Figure 3.15).  For the Asn194Asp virus, the amounts of viral particles 
bound to different cell lines are at the same level as shown by the similar fluorescent 
signals. For the Phe95Tyr/Asn194Asp virus, the signals are about 60% of the 
signals from the Asn194Asp virus in BHK21, Vero and A549, and about 80% in 
MDCK; indicating fewer viral particles bound to the cell surface for this variant. 
The NA activity of viral particles at 4 degree were monitored by using 
substrate MUNANA, and no NA activity was detected.  The results of the cell surface 
binding by recombinant viruses were not affected by the NA activity. 
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Figure 3.15 Fluorescence binding assays of recombinant viruses.  Alexa 488-
labeled viruses were bound to chilled cells in 96-well plates at an MOI of 3.0 and incubated at 4 
degree for 1 hour. The relative binding for each cell line is expressed as a percentage of 
Asn194Asp virus. 
3.3.  Structure of BHA2 at the post-fusion state 
3.3.1.  Data collection and processing 
The native dataset suffered from severe radiation damage as judged from the 
scale factor and B-factor profile from SCALA output.  The scale factors increased 
after 30 frames and the B-factor becomes smaller than -5 after 90 frames.  After 
screening for different derivative datasets, one dataset immersed in 1 mM Europium 
(Eu) was found to have less radiation damage.  The collection statistics for this 
derivative data are shown in Table 3.7.  The solution for this dataset was found by 
molecular replacement, and there is one chain of BHA2 in the asymmetric unit.  The 
biological trimeric state of BHA2 could be generated by rotation through the lattice 
3-fold symmetric axis. 
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Table 3.7 Data collection and refinement statistics. 
Data collection 
 
Wavelength (Å) 1.127 
Resolution range (Å) 37.76-2.45 (2.54-2.45) 
Space group R32 
Unit cell (a b c ) 48.18 48.18 354.895 90 90 120 
Total reflections 25553 
Unique reflections 5617 (584) 
Multiplicity 4.5 (4.4) 
Completeness (%) 89.43 (94.96) 
Mean I/sigma(I) 15.81 (5.21) 
Wilson B-factor (Å2) 40.44 
R-sym 0.053 (0.210) 
R-factor 0.2549 (0.2733) 
R-free 0.2681 (0.3333) 
Number of atoms 1111 
macromolecules 1084 
water 27 
Protein residues 142 
RMS(bonds) 0.005 
RMS(angles) 0.81 
Ramachandran favored (%) 91 
Ramachandran outliers (%) 2.9 
Clashscore 34.07 
Average B-factor (Å2) 53.2 
Macromolecules 53.4 
Solvent 44.4 
Statistics for the highest-resolution shell are shown in parentheses. 
3.3.2.  The overall fold of BHA2 
The sequence identity between BHA2 and AHA2 is only 29% as calculated by 
ClustalW2 (120).  Despite this low sequence identity (Figure 3.16), BHA2 is still able 
to fold into a hairpin-like structure (Figure 3.17A), which is very similar to AHA2 
(Figure 3.17B) (87, 88).  As for the predicted biological trimer, the common 
structural features between BHA2 and AHA2 include 1) the N-cap domain formed by 
the N-terminus of the long helix together with the C-terminus of BHA2, 2) the central 
coiled-coil assembled from helix A, B and C, 3) the six-helix bundle at the C-terminus 
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of the long helix and 4) the C-terminal fragment lying between the groove created 
by central helices. 
 
 
Figure 3.16 Protein sequence alignment of AHA2 and BHA2.  The central helix is 
shown in red, helix D is in blue, and helix G is in magenta. 
Overall, although the D-loop and the C-terminal fragment display some 
differences between AHA2 and BHA2, the coiled-coil regions resemble each other.  
The amino acid sequence alignment between AHA2 and BHA2 is shown in Figure 
3.16.  Residues 37 to 105 of BHA2 (AHA2 numbering) form the central helix, the 
length of which is same as that of AHA2.  The region between helix D and helix G of 
BHA2 lacks of secondary structure, and the density for this region is also weak 
suggesting great flexibility.  For the reported AHA2 structure where there are two 
trimers in one asymmetric unit, this region adopts different conformations including 
-helix, -sheet and random coil (87).  The length of helix G of BHA2 (5 residues) is 
shorter than that of AHA2 (11 residues) (Figure 3.16).  
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Figure 3.17 Overall fold of BHA2.  (A) The monomer of BHA2 is colored with structural 
elements. (B) The trimer of BHA2 (red) is superposed onto trimeric AHA2 (blue) (PDB accession 
code: 1QU1). The fusion peptides at the N-terminus of HA2 and transmembrane domain at the C-
terminus of HA are missing in the structures and are indicated as dash lines. The fusion peptide 
and transmembrane are brought into close proximity in the membrane (black rectangular) in 
the post-fusion state. 
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3.3.3.  The N-cap domain 
The N-cap domain ties together the N-termini of the coiled-coil and the C-
terminal residues.  The sequence identities among the N-cap domain (residues 35 to 
42) between BHA2 and AHA2 are extremely high as seen in Figure 3.16, suggesting 
similar interaction modes in this domain.  Asp37 makes hydrogen bonds by its 
carbonyl and carboxyl oxygen atoms with Lys39 and Ser40 to stabilize the N-
terminal end of the long helix.  Ala36 from three monomers forms a nonpolar layer 
stacking on a layer formed by Ala35 residues. 
A subtle difference between BHA2 and AHA2 is found in the N-cap domain.  
The C-terminal fragments of BHA2 attach to on another less tightly than those of 
AHA2.  As shown in Figure 3.18B, there are hydrophobic interactions between Val34 
and Ala175 in BHA2, with the distance between two closest atoms of 3.6 Å.  As 
shown in Figure 3.18A, the side-chain of Gln34 in AHA2 forms hydrogen bonds with 
carbonyl oxygen atoms of Gly175 and Val176, with the distance of 2.7 Å between the 
closest interacting atoms.  Further, the smaller residue Ala176 of BHA2 lies farther 
from the center of the triangle formed by the N-terminal residues than the larger 
residue Val176 of AHA2 does. 
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Figure 3.18 Interactions around the N-cap domain of AHA2 (A) and BHA2 (B).   
The first turn of the long helix is shown, and the N- and C-terminal residues are shown in stick 
mode with green and magenta for carbon atoms, respectively. The three-fold symmetric axis is 
shown by a small triangle. The side-chains of Val176 of AHA2 and Ala176 of BHA2 are 
highlighted to show their distances from the center of triangle. 
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3.3.4.  The long central coiled-coil 
By superimposing the central helix (residue 37 to 105) of BHA2 on the 
central helix of the AHA2 trimer based on their C atoms, the RMSD values for each 
pair of C atoms can be calculated as shown in Figure 3.19.  Some residues in helix A 
have small RMSD values, including Thr41, Ile45, Ile48 and Leu52.  These four 
residues are located at the inter-helical interface and are identical between BHA2 
and AHA2 (Figure 3.16).  The other residues in helix A show larger RMSD values, and 
these residues participate in the interactions with the C-terminal fragment, 
indicating a different interaction pattern for BHA2 and AHA2 between C-terminal 
fragment and the groove formed by the adjacent helix A. 
All residues from 59 to 72 have relatively large RMSD values, and these 
residues are all in helix B.  Helix B is formed from the loop-to-helix transition after 
HA is exposed to low pH, and this transition largely contributes to the dramatic 
conformational changes of HA.  There is only one identical residue in helix B (Glu72) 
(Figure 3.16), indicating that BHA2 employs different residues as compared with 
AHA2 not only for interaction with C-terminal fragment, but also for lining up the 
inter-helical interface around the helix B region. 
The residues from 77 to 98 in helix C have much smaller RMSD values in 
contrast to those in helix B.  This sequence also has more similarities (Figure 3.16), 
and structurally this region is shielded by the outer layer part including helix D to 
helix G, making it relatively constrained.  However, the residues at the end of the 
helix C (residues 100 to 105) display larger RMSD values, and these residues 
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interact with helix D to form the six-helix bundle, indicating that BHA2 must utilize a 
different strategy to stabilize a six-helix bundle, which is an important intermediate 
state during fusion. 
 
 
Figure 3.19 RMSD values for C atoms of the long central helix between BHA2 
and AHA2.  The BHA2 monomer is superimposed on each monomer of the AHA2 trimer by 
fitting their C atoms. The average RMSD values and standard deviations are shown. 
3.3.5.  The interaction between central coiled coil and C-terminal fragment 
The packing of the C-terminal fragment into the groove formed by the central 
helices will bring the C-terminal transmembrane domain in proximity to the fusion 
peptide. As illustrated by the RMSD profile, the helices A and B of BHA2 form the 
groove where the C-terminal fragment could dock, and BHA2 would be expected to 
employ different residues than AHA2 to stabilize this open hot-dog-like 
conformation, where the two strands of helices resemble two pieces of bread and 
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the C-terminal fragment the sausage.  To explore the detailed interaction mode in 
this region, the central helix, including helices A and B, and the C-terminal fragment 
are shown in detail (Figure 3.20).  Overall, it is found that in BHA2 (Figure 3.20B), 
the C-terminal fragment is in an extended state, and lies almost in the middle of two 
helices, making it a parallel conformation with the helices.  In contrast, the C-
terminal fragment in AHA2 (Figure 3.20A) reaches across from the C-terminus of 
one helix to the N-terminus of the other helix; the two helices and the C-terminal 
fragment form a “z”-like conformation. 
The length of the C-terminal fragment of BHA2 (16 residues) in this region is 
three-residues shorter than that of AHA2.  The hydrogen bonds in this region were 
predicted using Pymol and are shown by yellow dashed lines.  There are 34 pairs of 
hydrogen bonds in AHA2 between the C-terminal fragment and two helices, whereas 
only 9 pairs are found in BHA2 (Figure 3.20).  In contrast, more hydrophobic 
residues are found in the C-terminal fragment of BHA2, and these side-chains face 
toward the groove.  The residues include Phe157, Phe162, Leu164, Pro165, Phe167 
and Ile173, as shown in the ball mode in Fig.2.5B; in contrast, AHA2 only has Tyr157, 
Tyr162 and Ile173 (Figure 3.20A, residues in ball mode) that make contacts within 
the groove by hydrophobic interaction. 
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Figure 3.20 Interaction between C-terminal fragment with the groove formed 
by two adjacent helices (only helix A and helix B are shown) of AHA2 (A) and 
BHA2 (B).  The C-terminal fragment is shown in magenta. The residues involved in the 
interactions are shown in stick mode. Hydrogen bonds shown in yellow dashed lines were 
predicted by Pymol, and hydrophobic residues of C-terminal fragment facing toward the groove 
are shown in ball mode. 
3.3.6.  The six-helix bundle 
The six-helix bundle results from a helix-turn transition in a portion of the 
residues in helix C followed by the inverse packing of helix D against helix C, a 
characteristic intermediate that is observed for many enveloped viruses (121).  The 
formation of this six-helix bundle of influenza virus is required for the formation of 
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hemi-fusion state (83, 121).  To show the relative orientation of the six helices in the 
bundle, the structure is rotated to be viewed along the three-fold axis (Figure 3.21). 
In BHA2 (Figure 3.21B), Ile107 closely packs along the symmetry axis to form a tight 
hydrophobic core, surrounded by another layer provided by the hydrophobic 
residue Ile108.  In contrast, in BHA2, the carboxyl oxygen atoms of Glu105 at the end 
of helix C interact with the backbone atoms of Asn109 and Ser110 in the loop D of 
the adjacent chain, stabilizing the arrangement by multiple electrostatic interactions.  
The N-terminus of the helix D is located in the middle of two neighboring helix C in 
BHA2, as illustrated by two inversely placed regular triangles (Figure 3.21B). 
As compared with AHA2 (Figure 3.21A), Thr107 residues form an annulus 
that covers the C-terminus of the coiled-coil.  The hydroxyl group of Thr107 is also 
close to the carbonyl oxygen atom of Thr107 from the other chains.  Moreover, two 
hydrophobic residues Ile108 and Leu110 of AHA2 stack mainly between helix C and 
D, which pushes away the N-terminus of the helix D from helix C.  
The stacking orientation of the helix D against the two central helices C in 
BHA2 (Figure 3.21B, helix D is in warm pink) is also different from that in AHA2 
((Figure 3.21A, helix D is in sky-blue).  The helix D of BHA2 itself is straight, while 
that of AHA2 is a little bent. 
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Figure 3.21 Interaction between the loop D and helices in six helix bundle of 
AHA2 (A) and BHA2(B).  The central helices of coiled-coil are shown in blue in AHA2 and in 
red in BHA2.  The helices D are showin skyblue in AHA2 and in warmpink in BHA2. 
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To further characterize how helix D packs onto helix C in the six-helix bundle, 
the central coiled-coil is represented in surface mode, and one helix D is shown 
above the coiled-coil in Figure 3.22.  In BHA2 (Figure 3.22B), no larger residues are 
found to line the groove formed by two adjacent helix C segments, instead there is a 
cavity near Leu98. Leu118 in helix D of BHA2 is just located above the cavity and 
covers this region along with Leu115, Leu122 and Met125.  As compared with AHA2 
(Figure 3.22A), the surface formed between two neighboring helix C segments is 
rather flat due to the existence of two large hydrophobic residues Trp92 and Tyr94 
(BHA2 has Ile92 and Ser94 at the corresponding sites). 
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Figure 3.22 Packing of helix D on the neighboring helices C of AHA2 (A) and 
BHA2 (B) in the six-helix bundle.  The central coiled-coil is represented by surface mode. 
The helix C is shown in cartoon mode.  
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Chapter 4 
Discussion 
4.1.  Normal mode refinement improve the structural quality 
Structural refinement at limited resolutions is generally difficult and very 
inefficient.  Here it is presented the application of a new normal-mode-based X-ray 
crystallographic refinement method (NMRef) to a total of eight low-resolution 
crystal structures (in the range of 3.0~3.9 Å).  All these structures have low data-to-
parameter ratio (ranging from far below to barely 1.0).  The first two systems (PDB 
accession codes: 2A0L and 2BBJ) have very large average B-factors, indicating a high 
overall structural flexibility.  Two other systems (PDB accession codes: 2PM9 and 
1SUQ) contain structural regions with high B-factors. Possibly due to the limited 
data-to-parameter ratio, three systems (PDB accession codes: 2AEQ, 2INY and 2V1C) 
have a constant B-factor for all atoms, and one system (PDB accession code: 2BBJ) 
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has an almost constant B-factor for all atoms.  Of the eight structures, three are 
membrane proteins, and five are soluble supramolecular complexes. 
In all cases, the application of NMRef substantially improved the fit between 
the structural models and the diffraction data as reflected in the decreases of R-
factors (Figure 4.1).  The decreases are in the range of 1.7% ~ 7.7% for Rfree-factors 
and 1.5% ~ 14.8% for Rcryst-factors.  The averaged decreases are 3.6% for Rfree-
factor and 4.8% for Rcryst-factor. In addition, in most cases, there is a concomitant 
improvement in the geometry of the structural model, as reflected in the 
improvement of residue distribution in the Ramachandran plot and reduction in the 
number of bad contacts.  It is worth emphasizing that these substantial 
improvements were achieved in only one round of normal-mode-based refinement 
without any manual adjustment, with 5~100 fold fewer thermal parameters than in 
the original isotropic B-factor refinement.  As demonstrated in the previous studies, 
the use of multiple rounds of normal-mode refinement generally brings about much 
more substantial improvements (50). 
Since TLS refinement uses a different concept, whether the combined use of 
TLS with normal-mode refinement will result in further improvement is tested.  
Indeed, in about half cases, the application of TLS to normal-mode refined 
structures further decreased the R-factors and sometimes improved the geometry 
as well.  The most significant advantage of NMRef over TLS is seen in the last three 
systems in Figure 4.1.  In these systems, the isotropic B-factors were set as a 
constant in the final structures deposited in PDB, which made the direct application 
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of multi-group TLS refinement impossible. The application of NMRef is not at all 
affected by the values of isotropic B-factors. However, in certain cases, the TLS 
refinement may deliver better R-factor improvement than NMRef. This result arises 
from the independence of body motion in TLS that may offer a greater flexibility for 
fitting in cases where structural deformations are less collective. 
As clearly indicated from the study on these test systems, testing the normal-
mode refinement using a different number of lowest-frequency normal modes is a 
useful approach.  In real applications, testing the combined use of normal-mode 
refinement with TLS, which in some cases can result in further improvement in 
structural refinement, is also useful.  Even for the cases where TLS outperforms 
NMRef, an initial application of NMRef may improve the subsequent application of 
TLS because the former can deliver a smoother B-factor distribution for better 
grouping of TLS. 
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Figure 4.1 Structural improvements produced by normal-mode refinement 
over the original models.  (a) Decreases in R factors. Grey bars represent decreases in Rcryst 
and black bars those in Rfree. (b) Percentage of residues distributed in the Ramachandran 
favored region and (c) percentage of residues distributed in the Ramachandran outlier region, 
as calculated using MolProbity (114). Grey bars are for the original models and black bars are 
for the normal-mode refined models. 
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4.2.  Phe95Tyr increases the receptor-binding affinity of 
influenza BHA 
Compared with influenza A virus, naturally occurring influenza B virus has a 
much lower binding affinity for synthetic glycans and natural receptors on the cell 
surface (94).  Previous structural studies of influenza BHA indicated a critical 
difference between the HA glycoproteins of influenza A and B viruses at the bottom 
of the receptor binding sites, Tyr98 in AHA versus Phe95 in BHA (69, 70).  Given the 
absolutely conserved nature of Tyr98 among all known 16 subtypes of influenza 
AHA proteins, the presence of Phe95 in BHA might be responsible for the lower 
receptor binding affinity of influenza B virus (Figure 1.4).  
By using recombinant influenza BHA and its designed variants, the results 
demonstrate that Phe95Tyr is able to enhance the binding affinity of BHA to 
synthetic glycans significantly (Figure 3.10, Table 3.4), corresponding to a level 
comparable to those of influenza A virus (64, 122–124) and allowed BHA to bind red 
blood cells from many different animals (Figure 3.12) that are known to contain a 
great deal of variation in cell-surface glycan compositions.  Most significantly, the 
“corrective” mutation can competitively block the binding and infection of influenza 
A virus (Figure 3.13) and greatly improve the binding of mutant BHA to all three cell 
lines that showed very low binding to wild-type BHA (Figure 3.14).   
An outstanding feature of the improved receptor binding affinity by the 
“corrective” mutation, Phe95Tyr, is the almost indiscriminate enhancement 
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towards both human-like and avian-like receptors (Figure 3.10, Table 3.4).  This 
binding improvement is postulated to be the fact that the Sia-1 moiety interacts with 
the hydroxyl group of Tyr98 of H3 AHA via two hydrogen bonds (Figure 1.4A), a 
pattern shared by both types of receptors.  Thus, it is expected the introduced 
hydroxyl group of Tyr95 in BHA to make similar interactions with the Sia-1 moiety.  
To confirm that this arrangement is structurally feasible, this mutation in the BHA 
crystal structure is made in silico (PDB accession code: 2RFU) (70).  With only minor 
adjustment, the side-chain of Tyr95 was readily placed to a position similar to that 
of Tyr98 in H3 AHA, and similarly makes two hydrogen bonds with the Sia-1 moiety 
and one hydrogen bond with His191, another key residue of the RBS (Figure 1.4C).  
This hypothesis was further supported by a glycan array analysis in which 
Phe95Tyr and Phe95Tyr/Asn194Asp mutants were able to bind significantly 
better to the glycan containing only the Sia-1 moiety than wild-type and 
Asn194Asp BHAs, respectively (Figure 3.10) (125). 
In the binding competition assay (Figure 3.13), the ability of BHA or its 
various mutants to inhibit the binding of influenza A virus appeared to be closely 
related to the receptor binding affinity of corresponding BHA glycoproteins to 
(2,6)-linked receptors (Table 3.4).  For instance, the slightly better binding of wild-
type BHA, compared to that of Asn194Asp, corresponded to slightly stronger 
inhibition against influenza A virus.  Similarly, the 10-fold higher binding affinity of 
Phe95Tyr/Asn194Asp over that of Phe95Tyr resulted in at least four-fold of 
stronger inhibition.  This result is presumably because the influenza A virus that 
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used in this assay, an A/Brisbane/10/2007-like strain, is a human strain that would 
preferentially bind to (2,6)-linked sialic acid receptors.  Thus, the better the 
binding affinity of BHA to (2,6)-linked sialic acid receptors, the fewer the (2,6)-
linked sialic acid receptors remain accessible for A/Brisbane/ 10/2007-like viruses 
to attach and invade the cells and, consequently, lower the viral titers.  Moreover, 
although MDCK cells have both (2,6)-linked and (2,3)-linked sialic acid receptors, 
the former is thought to be in a much higher abundance than the latter (126).  
Due to the complexity of sialic acid presentations on cell surface, a 
quantitative calculation of apparent dissociation constants between BHA and three 
cultured cell lines was not possible.  However, if the relative intensity of wild type is 
compared with the Phe95Tyr mutant at the highest BHA concentration (both 
were not saturated), about 5~10 fold better binding for Phe95Tyr mutant (Figure 
3.14B) over the wild type (Figure 3.14A) is seen.  Furthermore, if comparing the 
concentration at which 50% relative intensity was achieved for Asn194Asp 
(Figure 3.14C) and Phe95Tyr/Asn194Asp (Figure 3.14D) (since the saturation 
was observed at higher Phe95Tyr/Asn194Asp concentration), binding for the 
protein with the Phe95Tyr mutation is 30~60 fold better.  Therefore, the 
Phe95Tyr mutation significantly promotes the binding of BHA to the surface of all 
three tested cultured cell lines. 
Interestingly, the enhanced signal by the side-chain of the mutation of 
Phe95Tyr in this study can be accommodated in the receptor binding site of BHA 
easily and moreover greatly enhances the receptor binding affinity. In sharp 
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contrast, the large-to-small mutation of Tyr98Phe on H3 AHA almost abolished 
the binding of influenza A virus to red blood cells, and the recombinant Tyr98Phe 
virus cannot infect mutant MDCK cells with a reduced level of cell-surface sialic 
acids (127).  Since Tyr98 contributes one hydrogen bond to stabilize the RBS and 
two additional ones to bind to the sialic acid receptors (128), it is likely that 
Tyr98Phe somehow distorts the RBS and/or substantially weakens the receptor 
binding in H3 AHA.  Nevertheless, the fact that wild-type BHA can still bind to sialic 
acid receptors and red blood cells, albeit at a lower affinity, suggests that the loss of 
the hydroxyl group in Phe95 has been at least partially compensated, perhaps by 
some small local structural adjustments such as those found within the 240-loop 
and 140-loop (70). 
4.3.  The roles of receptor binding of HA in influenza virus 
pathogenicity 
Recent studies on influenza A virus have demonstrated that manipulating 
receptor-binding avidity is an important tool that influenza A virus can use in 
response to neutralization imposed by neutralizing antibodies, which seems to drive 
antigenic drift (129).  Moreover, a single base-pair change in 2009 H1N1 AHA 
increased its binding affinity for human receptors, corrected the low receptor 
affinity of the field isolate, and led to efficient airborne transmission in ferrets (122).  
These and other studies (123, 124, 130) suggest that the binding affinity of AHA to 
receptors is an important determinant for influenza infectivity. 
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The lack of reservoirs of influenza B virus outside of human population is 
believed to be one of the major reasons that influenza B virus does not undergo 
antigenic shift, a molecular evolutionary mechanism that is responsible for all 
known human pandemics caused by influenza A virus (71, 128, 131).  It remains an 
open question whether there exists a correlation between the limited host range 
and the lower receptor binding affinity of BHA of natural influenza B virus.  Most 
recently, Palese and co-workers (132) published an interesting study in which the 
ectodomain of influenza PR8 H1 AHA was used to replace that of influenza BHA in 
recombinant influenza B virus.  In marked contrast to the wild-type influenza B 
virus, the recombinant influenza B virus with inserted PR8 H1 AHA resulted in 
significant weight loss in infected mice, suggesting that PR8 H1 AHA has somehow 
enhanced the pathogenicity of the recombinant virus in which it resides. 
Taken together, the substantially enhanced receptor binding affinity of BHA 
upon a single Phe95Tyr mutation at the RBS site provides a plausible explanation 
for the very limited host range displayed by influenza B virus.  As suggested in 
previous studies e.g., (127), a sufficient density of cell-surface sialic acids with a 
weaker receptor-binding HA or a lower than optimal density of sialic acids with a 
stronger receptor-binding HA are both viable combinations for effective influenza 
infection.  Thus, the weaker receptor binding of wild-type BHA imposes a much 
higher demand for the “perfect” glycan composition on the surface of target cells in 
a given host; thus, influenza B virus only infects hosts that satisfy such strict 
requirement.  A single Phe95Tyr mutation was able to promote the binding 
affinity of BHA to a comparable level as that of AHA, regardless of human or avian-
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like receptors, thus enabling BHA to bind a much wider range of red blood cells and 
three cultured cell lines where the wild-type BHA binds very poorly.  Although it is 
not known when, how and why influenza BHA acquired Tyr95Phe mutation in the 
course of evolution, it is likely that some or all of the other 10 viral proteins of 
influenza B virus have undergone concomitant changes to maintain a delicate 
balance between BHA and neuraminidase (133).  Although the data revealed the 
importance of a single-residue mutation at the receptor binding site to the receptor 
binding affinity of BHA, further studies are needed to explore implications for 
pathogenicity and evolution of influenza B virus. 
4.4.  The increased receptor binding ability of BHA alone may 
not be advantageous to the replication of viruses 
Our studies based on the recombinant proteins show that the Phe95Tyr 
mutation increased the receptor binding ability of BHA toward synthetic and natural 
receptors at protein level.  However, the replication of the 
Phe95Tyr/Asn194Asp virus in mice is not as robust as that of the Asn194Asp 
virus (Table 3.5).  The HA titer of the Phe95Tyr/Asn194Asp virus against 
chicken, turkey and guinea pig erythrocytes is much lower than that of the 
Asn194Asp virus when the reactions are incubated at 4 degree for 2 h (Table 3.6).  
Moreover, the fluorescently labeled virus binding assay indicates that there are 
about 20%~40% fewer Phe95Tyr/Asn194Asp viral particles bound to the four 
different cell lines (Figure 3.15).  Nevertheless, Phe95Tyr/Asn194Asp viruses 
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are still able to agglutinate erythrocytes of three species after incubating at 37 
degree for overnight whereas Asn194Asp completely loses this ability (Table 3.6).  
Two possible explanations for this observation include: 1) the mutated BHA binds to 
a receptor that neuraminidase could not recognize, or 2) the mutated BHA binds to 
the receptor so tightly that access of neuraminidase to the receptor is less efficient.  
As shown by previous studies, the balance between HA and NA is important for the 
replication of influenza virus(134, 135).  The attenuated replication of the 
Phe95Tyr/Asn194Asp virus in mice may be a result of imbalance between the 
high receptor binding affinity of BHA with other components of influenza B virus 
that have changed to accommodate the low BHA binding affinity.  Further 
experiments are needed to test these possibilities. 
4.5.  Structure of  BHA2  
The influenza virus HA protein is a member of class I viral fusion proteins, 
which are characterized by trimeric hairpin structures containing a central coiled-
coil. Human immunodeficiency virus 1 gp41, Ebola virus gp2 and human 
Parainfluenza virus F also belong to this class of viral fusion proteins (82, 136).  
Studies on protein-mediated membrane fusion by these proteins not only reveal the 
mechanisms by which viruses merge with host membranes, but also identify those 
principles guiding the communication between cell compartments, including, for 
example, plasma-membrane repair and endosome-lysosome fusion (85, 137, 138).  
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The studies on the viral fusion proteins will contribute to the explanation of the 
evolutionary principles of membrane fusion (84). 
Early knowledge regarding membrane fusion came largely from studies of 
influenza A virus HA, and the spring-loaded mechanism was proposed based on the 
finding that the synthetic 36-residue long peptide comprising the B-loop of AHA2 
folded into a three-stranded coiled coil in solution (89).  The neutral pH form of AHA 
in the pre-fusion state was thought to be meta-stable, and the energy stored in this 
state was released to induce hemifusion triggered by low pH (121, 139, 140).  At a 
later stage, the formation of the hairpin-like conformation was crucial to the 
opening and enlargement of the fusion pore (121, 141). 
Although class I viral fusion proteins from different viruses are unrelated in 
protein sequence, these proteins show some common structural features, including 
a six-helix bundle (136).  Whether BHA2 would fold into a hairpin conformation 
similar to AHA2 or is precluded from doing so due to the lack of structure of BHA in 
the post-fusion state remains unknown.  Analysis of the structure of BHA2 together 
with the reported AHA2 structure demonstrates some unique interaction modes in 
those structural elements common for class I viral fusion proteins, and this analysis 
provides detailed information on how divergent protein sequences could evolve to 
share the spring-loaded mechanism for fusion. 
Importantly, the B-loop of AHA2 has two large residues Phe63 and Phe70, 
which are thought to be the key residues for the formation of newly formed coiled 
coil (90, 142), whereas BHA2 has Leu63 and Met70 at corresponding sites.  BHA2 and 
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AHA2 have extreme sequence diversity in the B-loop (Figure 3.16) and they also 
show large structural differences (Figure 3.19).  Considering the important role of 
the B-loop in the conformational change, the sequence difference might be 
interpreted to signal the divergence of BHA and AHA structure and function.  On the 
contrary, the B-loop of BHA2 has higher probability (Figure 4.2) to form coiled-coil 
structure than that of AHA2 calculated by the COILS/PCOILS webserver 
(http://toolkit.tuebingen.mpg.de/pcoils) (143).  This result indicates that the B-loop 
of BHA2 may form a coiled-coil despite the fact that it lacks the two Phe residues.  
However, this protein may have a different folding pathway to form the coiled-coil 
as compared with AHA2. 
 
Figure 4.2 The coiled coil probability of AHA2 (A) and BHA2 (B) predicted by 
the COILS/PCOILS server.  The prediction is calculated with different lengths of residues as 
window size (14, 21 or 28 residues) shown in different colors. The B-loop of AHA2 includes 
residues 56 to 75 and the B-loop of BHA2 includes 58 to 74. 
His74 is located at the C-terminal end of the B-loop in BHA. The loop 
conformation around His74 is stabilized by its interaction with Glu76 on the 
neighboring chain (Figure 4.3) as observed in the pre-fusion BHA structure (69).  In 
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group 2 AHA, a conserved His106 is found at the N-terminus of the D-loop; whereas 
a conserved Arg106 is in group 1 AHA.  When an Arg106His mutation is 
introduced to H2 AHA (group 1), this side-chain interacts with Glu105 on the 
neighboring chain in the pre-fusion state to retain the helical conformation around 
His106 even under acidic condition.  The results for Arg106His in H2 AHA lead to 
an inference that the stabilization of this residue of HA2 in the pre-fusion state might 
affect the fusion ability HA. Histidine residues are often considered as triggers of 
conformational changes, the so-called “histidine switch” (144, 145).  To establish 
whether His74 of BHA2 is key to the fusion ability of influenza virus will require 
further studies. 
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Figure 4.3 His74 located at the C-terminal end of B-loop of BHA forms 
hydrogen bond with Glu76 of neighboring chain (PDB accession code: 3BT6). 
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The side-chain of Glu59 in the B-loop of BHA2 points toward the three-fold 
axis (Figure 4.4).  A buried glutamate residue is found to be responsible for the 
conformational change induced by low pH in synthetic peptides based on 
macrophage scavenger receptors (146).  In the study of those synthetic peptides 
(146), the peptides adopted a random coil structure at neutral pH, and the peptides 
became an -helical coiled-coil at pH 5.  The glutamate in the synthetic peptides was 
found to be crucial for the pH-induced conformational change.  For BHA at the 
neutral pH form (69), Glu59 is also located in a loop region (N-terminus of B-loop), it 
is reasonable to assume that this residue serves as the pH sensor when BHA is 
protonated in the low pH environment of endosome.  The protonation of Glu59 will 
reduces the electrostatic repulsion of this charged residue from each other and 
facilitates the burial of Glu59 in the interior of the coiled-coil.  However, BHA2 alone 
(without BHA1) is still able to form hairpin conformation at the neutral pH.  The 
unanswered question is that how the charged Glu59 is stabilized in the BHA2 
structure.  In the BHA2 structure (Figure 4.4), Glu59 is surrounded by residues, 
including Asn52, Leu53 and Leu164,  that may help the burial of the charged residue 
in the hydrophobic core. 
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Figure 4.4 Glu59 in the B loop of BHA2 faces inward and is stacked by the 
surrounding large residues.  The -weighted 2FOFC map is shown at 2 level. 
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Chapter 5 
Conclusions 
Influenza B virus remains a health threat to people all over the world.  The 
studies on the structural and functional properties of influenza B virus HA (BHA) 
will further the understanding of this virus.  The normal mode refinement (NMRef) 
is a useful method to improve the fit between the structural model and diffraction 
data especially for the structures determined at low resolution and the structures 
with high flexibilities.  By applying the NMRef method, quality of the structural 
model is improved and thereby facilitating the more accurate interpretation of the 
interaction patterns in the structure.  The usefulness of the NMRef method will 
possibly be demonstrated on the BHA-antibody crystal structures in the future. 
The introduction of Tyr at site 95 in BHA protein could increase the receptor 
binding affinity of BHA at the protein level.  However, recombinant viruses with 
Phe95Tyr mutation in BHA do not clearly display the increased receptor binding 
affinity.  The imbalance between the high receptor binding affinity of BHA and un-
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modified receptor cleavage ability of influenza B virus NA may affect the 
pathogenesis of influenza B virus; thus, affecting the receptor binding affinity of the 
virus.  However, how this imbalance affects the pathogenesis of influenza B virus 
requires further investigations.  This study also illustrates the importance and 
necessity of the co-evolution of HA and NA of influenza viruses.  
The structure of BHA2 at the post-fusion state presents the detailed 
interaction modes that are involved in the stabilization of the hairpin-like 
conformation of BHA2.  By comparing the BHA2 model with the reported AHA2 
structure (87),  it shows how diverse protein sequences between AHA2 and BHA2 
may fold into similar conformation.  The structure of BHA2 could be the basis for 
further investigation of the fusion mechanism for influenza B virus. 
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Notes 
1. Results for the normal mode refinement on eight systems have been 
published in Acta Crystallography. Section D. Biological Crystallography 
(2009), 65, 633-643 . 
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